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Abstract
Copy number variation (CNV) of DNA fragments is a particular type of structural genetic
variation. The characterization of CNVs has been an instrumental tool to understand
different diseases. As an example, gene copy number alterations are frequent in cancer
cells.
In this study, we present a Bayesian inferential framework to detect and identify CNVs the
exonic regions of protein-coding-genes. Using the coverage readings from next-generation
sequencing methodologies, we propose to standardize the case study coverage using a refer-
ence coverage. A hierarchical robust model with a normal likelihood is then implemented
to assess the posterior distribution of each the exonic coverage ratio means. Markov Chain
Monte Carlo via Hamiltonian Monte Carlo was performed to obtain random samples from
the posterior distribution.
We present and discuss a case study with the BRCA1 and BRCA2 genes. The coverage
standardization using a reference coverage is not affected by the existence of coverage
readings from exonic CNVs. The use of a robust approach adds explanatory value to the
model. The identification of CNVs proves straightforward using exon-specific Bayes factors.
Values above 2 appear to be sufficient to properly identify true CNVs, but most important,
eliminate artifact CNVs. In addition, an increased scale parameter in the distribution of the
exonic coverage means, appears to be a promising pattern to detect CNVs, in a preliminary
phase.
We conclude that the robust hierarchical Bayesian model satisfactory identifies and charac-
terize exonic CNVs in protein-coding-genes. Our model was validated in the BRCAs genes,
but may be generalized for any gene we might want to study.
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Notation
Gelman et al. (2014a) notation is adopted in this thesis.
We opt for a compact notation format, that in some cases can be an abuse of the standard
mathematical notation, it is more intuitive in others. p(.) is interpreted as the probability of
a specific event or the marginal probability distribution. p(.|.) is the conditional probability
density, with specified arguments on the right. Often conditioning quantities are implicit,
however, conditioning on the data p(.|y) will always be indicated.
Observations are symbolized as y, while the predictive data (future observations) are denoted
as y∗.
Continuous and discrete distributions are equally treated.
When standard probability distributions are used, a notation based on the name of the
distribution is preferred. If θ has a normal density probability function with mean µ and
variance σ2, then we write p(θ|µ, σ2) = N(θ|θ, σ2). Similarly, we use the notation θ ∼
N(µ, σ2) to specify random variables.
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Preface
The main objective of this thesis is to create an inferential model which permits to detect
and identify CNVs on the exonic regions of genes. Such a problem requires both theoretical
and applied considerations. We opt for a thesis organization that separates the theoretical
background, necessary to understand the inferential approach and associated methodologies,
from the biological problem, that includes the model construction and analysis.
Chapters 1 and 2 are meant to introduce the main concepts of the Bayesian inference and
computation. Those who are familiar with the Bayesian inferential approach to probability
and MCMC methodologies are free to skip these chapters.
Chapters 3, 4, 5 and 6 are devoted to the biological problem of CNV detection and identi-
fication. These core chapters include the data description, model building and assessment
and model utility in the context of the biological problem.
1
Chapter 1
Introduction to Bayesian statistics
Bayes’ solution to a problem of inverse probability was presented in An Essay towards solving
a Problem in the Doctrine of Chances (Bayes and Price, 1763), published by the Royal
Society in 1763 after Bayes’ death. This essay contains a statement of a special case of the
Bayes’s theorem and can be considered the first historical milestone of Bayesian statistics
(figure 1.1). Chapter 1 intends to give an overview of the fundamentals of Bayesian inference
and statistics.
Figure 1.1. Reverend Thomas Bayes (1702-1761) and an excerpt of the An Essay towards solving a Problem
in the Doctrine of Chances (1763) where the problem of the inverse probability is stated.
2
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1.1 Probability as uncertainty
In Bayesian statistics probability is understood as a measure of uncertainty (Bernardo,
2003). Bayesian approach uses prior knowledge of the study phenomenon together with
the information that can be retrieved from the data, to estimate population parameters
(Gelman et al., 2014a).
1.1.1 Bayesian knowledge
The introduction of prior information that may exist about the problem (including familiarity
with the phenomenon or studies that have been carried out) is one of the major novelties
of the Bayesian statistics (Gelman, 2002a). In fact, in most cases there are typically a set
of data (even if sparse) or prior information about the process to be modeled. The general
principle is simple, whatever the state of knowledge about some phenomenon, it can be
expressed as a probability distribution (Bernardo, 2003).
The Bayesian statistics provides a natural method to introduce uncertainty accounting for
experimental evidence: the knowledge concerned to the phenomenon or judgments formed
prior to the random experience are mathematically expressed as a prior distribution, and
information contained in data, belonging to a certain parametric family, are expressed as a
likelihood function (Hoff, 2009). Combining the prior distribution and the likelihood func-
tion, we can obtain the posterior probability distribution, which expresses our uncertainty
reviewed in the light of the data (Gelman et al., 2014a).
1.2 Bayesian Inference
In the Bayesian approach, the basis for the statistical procedure is the combination of any
new probabilistic information to that one which is already available. Bayes’ rule provides a
formal framework to update beliefs in light of new information, being, as its name implies,
the basis of the Bayesian inference (Gelman et al., 2014a).
Baye’s theorem implicitly defines the conditional distribution of parameters given the data,
i.e. the posterior distribution (Hoff, 2009). Consider that θ is an unobserved parameter
(possibly a vector) and y = (y1, ..., yn) an observed random sample of size n. The Bayes’
rule states,
p(θ|y) = p(θ, y)
p(y)
=
p(θ, y)∫
Θ p(θ, y)dθ
=
p(y|θ)p(θ)∫
Θ p(y|θ)p(θ)dθ
The term in the denominator does not depend on θ, thus the posterior distribution can be
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simply expressed by the product,
p(θ|y) ∝ p(y|θ)p(θ)
Bayes’ rule jointly integrates the prior information about the random experience and the
sample information (Gelman et al., 2014a). Formally, the prior distribution p(θ) expresses
the initial knowledge about θ prior observing y; the likelihood p(y|θ) describes the process
giving rise to the data in terms of unknown θ; and the posterior distribution p(θ|y) is the
probability recalculated based on the likelihood and the prior distribution, expressing what
is known about θ after observing y (Hoff, 2009).
The posterior distribution gives us a refined estimate of θ (Gelman et al., 2014e). It can be
showed that the prior variance can be decomposed in the terms,
V (θ) = E[V (θ|y)] + V [E(θ|y)]
The expected posterior variance is on average lower than the prior variance by V [E(θ|y)],
which corresponds to the information we expect the experiment to provide (Gelman et al.,
2014e).
Bayesian inference becomes straightforward when the posterior is determined (directly or
simulated). Inferences in Bayesian statistics are always based on a posterior probability
distribution of θ, which includes point and interval estimates and also hypotheses testing.
1.2.1 Point estimates
In the Bayesian approach the posterior distribution is used to estimate the parameters under
study. However, the estimators of θ must respect quality criteria. To obtain the quality
status of the Bayesian estimators we use the loss function L(θ, a), which measures the loss of
using the value a to estimate the parameter θ. The optimal estimate is chosen to minimize
the expected loss E[L(θ, θˆ)], calculated on the posterior distribution p(θ|x) (Ghosh et al.,
2006).
Two types of loss functions are commonly used: the quadratic loss function (L = (a− θ)2)
and the absolute loss function (L = |a− θ|) (Carlin and Louis, 2009a). The posterior mean
minimizes the posterior expected loss for the quadratic loss function. The posterior median
minimizes the posterior risk for the absolute-value loss function. Other point etimators exist,
as the posterior maximum (Carlin and Louis, 2009a). The posterior maximum finds the
maximum of the posterior distribution an can be useful summarizing skewed distributions.
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1.2.2 Interval estimates
In addition to point summaries, it is nearly important to report posterior uncertainty. A
credible interval is an interval in the domain of the posterior probability distribution. A
central interval for θ at (1 − α) of posterior probability corresponds to the range of values
(a, b) above and below which lies exactly α/2 of the posterior probability (Ghosh et al.,
2006).
p(a ≤ θ ≤ b|y) ≥ (1− α)
Where α is a small positive number between 0 and 1.
A slightly different summary of the posterior parameter uncertainty is the highest posterior
density region, defined as the region R that contains (1− α) of posterior probability, but in
which the density within the region is never lower than that outside (Ghosh et al., 2006).
p(θ0|y) ≥ p(θ1|y) ∀ θ0 ∈ R, θ1 /∈ R
For unimodal, more-or-less symmetric distributions, highest posterior density based and
quantile-based credible intervals would not be too different. But when the posterior densities
become more complex (bimodal with well-separated modes) the highest posterior density
credible region are two disjoint intervals, whereas the central quantile-based credible region
is a single interval by construction (Gelman et al., 2014e).
In Bayesian inference it makes sense to enunciate the Bayesian credibility intervals (or
regions), as a state of probability. A legitimate interpretation of Bayesian credibility regions
is that, given the information we observed, we are (1− α) confident that the true value of θ
is within the obtained interval (or region) (Ghosh et al., 2006).
1.2.3 Hypothesis testing
The Bayesian approach to hypothesis testing is quite simple and intuitive. Consider the
hypothesis testing problem:
H0 : θ ∈ Θ0 vs. H1 : θ ∈ Θ1
Where Θ0 and Θ1 are compound hypothesis. We can define the posterior probability of each
hypothesis as λ0 and λ1:
λ0 = p(θ ∈ Θ0|y) and λ1 = p(θ ∈ Θ1|y)
λ0 and λ1 can be used to conclude which hypothesis must be considered. If λ0 > λ1 we have
favorable posterior information to accept H0, on the contrary, if λ1 > λ0 the hypothesis H1
is more likely and we should reject H0. To accept or to reject one of the hypotheses the ratio
6 CHAPTER 1. INTRODUCTION TO BAYESIAN STATISTICS
between λ0 and λ1 probabilities is commonly used: the Bayes factor (BF). (Ghosh et al.,
2006).
BF =
λ0
λ1
=
p(θ0|y)
p(θ1|y) =
p(y|θ0)
p(y|θ1)
p(θ0)
p(θ1)
The Bayes factor is used considering the Jeffrey criterion, which state that the hypothesis
with an odd ratio higher than 1 should be favored (Ghosh et al., 2006). The Bayes factor can
be also used as a degree of confidence: a Bayes factor bigger that 10 is generally seen as strong
evidence while bigger that 20 is decisive evidence for the numerator model/hypotheses.
The Bayesian hypothesis testing can include a loss function L(θ), which integrates the
posterior risk. Using a risk function in the Bayes factor to determine the best choice among
several is nothing else than a probabilistic optimization problem. These type of problems
arise naturally in the Bayesian framework, when more than probabilities are needed to be
accounted (money, time, security, efficiency, ...).
1.2.4 Predictive distribution
Predictive distributions are widely used in Bayesian statistics during the model assessment
phase. We have been using the posterior distribution p(θ|y) broadly in inference, but we
can be interested in make predictive probabilistic statements about an unobserved quantity
(a future observation) y∗, considering the obtained observed data y = (y1, ..., yn). Predic-
tive inferences rely in the posterior predictive distribution p(y∗|y), which is a conditional
distribution on the observed values (Gelman et al., 2014g).
The posterior predictive distribution can be defined using the posterior distribution,
p(y∗|y) =
∫
p(y∗|θ)p(θ|y)dθ
which implies that future data is independent of past data, conditional on the parameters
(Gelman et al., 2014g). The posterior predictive distribution is obtained by integrating the
product of the data model distribution p(θ|y) with the posterior distribution with respect
to the model parameters p(y∗|θ). In consequence, the posterior predictive distribution has
the same mean as the posterior distribution, but a greater variance, due to the additional
sampling uncertainty (Gelman et al., 2014g; Gelman and Shalizi, 2013).
In some cases the form of p(y∗|y) can be derived directly, but it is often easier to sample from
p(y∗|y) using Monte Carlo iterates (say L) that we might have from the posterior distribution:
a random vector of parameters θl can be obtained from the posterior distribution and used
to simulate y∗ according to the p(y∗|θl) distribution. y∗ = (y∗1, ..., y∗l , ..., y∗L) is a random
sample from p(y∗|y) (Albert, 2009a).
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1.3 Prior distribution
Bayesian inference includes two sources of assumptions, the likelihood and the prior distri-
bution. The use of a prior distribution caused distrust and criticism from other probability
schools (Kass and Wasserman, 1996), being known as subjective for several decades (Gelman
et al., 2014a). However, this sobriquet was unfairly received since any type of probability
statement is subjective. There are many aspects to take into account choosing a prior distri-
bution: some are choose for mathematical convenience, others to express lack of information,
and others to specify information about parameters (Kass and Wasserman, 1996). Thus,
the prior distribution may be as generic and uninformative as one wants, or alternatively,
integrate data from past experiences (Gelman, 2002b), making the whole Bayesian process
objective.
In many problems there is no relevant information on the parameters of interest and a non-
informative prior should be considered. When some information is available a informative
prior could be used, but the prior should not be too stringent, because it can limit the
posterior distribution to evaluate the prior zero density regions. A good property of priors is
that the influence of the prior generally goes to zero as we collect more data, given prevalence
to the observational information (Kass and Wasserman, 1996).
1.3.1 Conjugate priors
A prior is conjugate for a family of distributions if the prior and the posterior are of the same
distributional family (Gelman et al., 2014e). Exponential families have conjugate priors in
general (Kass and Wasserman, 1996), in which the likelihood, considered in terms of the
parameters, has a kernel in the same form as the prior distribution.
Conjugate prior are preferable because they generally simplify obtaining posterior distribu-
tions and/or obtaining marginal/conditional posterior distributions (Kass and Wasserman,
1996). In addition, the conjugate priors can be either informative or non-informative,
depending on the chose parameter values (Gelman et al., 2014e).
1.3.2 Non-informative priors
A prior distribution is non-informative if the prior is flat relative to the likelihood function,
returning that, it has minimal impact on the posterior distribution of θ (Gelman, 2002b).
The uniform distribution or the normal distribution with variance large enough, are good
examples of non-informative priors.
An additional care with non-informative prior must be considered: the propriety property
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(Kass and Wasserman, 1996). A prior p(θ) is improper if,∫
Θ
p(θ)dθ =∞
The propriety property implies that the kernel of the prior must integrate to a finite number.
Improper priors may result in proper or improper posteriors, but in the last case, we are
not in conditions to proceed to inference (Kass and Wasserman, 1996). The use of improper
priors require the additional effort of knowing if the posterior is proper.
Improper priors are often used because they are generally non-informative. In practical
cases, the improper priors use can be justified when the data are informative enough about
the parameter of interest, thus we do not need specifying our ignorance exactly (Gelman
et al., 2014e). If there are lack of data, the use of a improper prior is not recommended
(Kass and Wasserman, 1996).
1.3.3 Informative priors
Informative priors are not dominated by the likelihood, and therefore have a considerable
impact on the posterior (Gelman, 2002b).
Usually the main challenge of using informative priors is to choose a reasonable distributional
family. Some choices are obvious: a normal or a t-student distribution are well suited for real
parameters; gamma, inverse-gamma and log-normal are adequate for precision parameters
and variance components; beta distribution fits parameters ranging in the [0, 1] interval
(Gelman et al., 2014e). Once a prior family, and particular parameter values are chosen
(mean, variance, shape, scale), it is recommended to verify if the statistical summaries of
the prior are consistent with our prior beliefs (Gelman et al., 2014e).
1.4 Interpretations of probability
The Bayesian and Classical methods (meaning Frequentist) collide mainly in the way they
interpret the parameters and data that are subjected to inference (Lindley, 2000). Classic
inference is represented by Neymann, Pearson and Wald and respects the orthodox view
that sampling is infinite and decision rules can be sharp. Data is seen as a repeatable
random sample (there is a frequency), in which the underlying population parameters remain
constant during the repeatable process (Gelman and Shalizi, 2013). Bayesian appears with
Bayes, Laplace and de Finneti, and is characterized by threatening probabilistically any
unknown quantity, which can always be updated. Data are finite and observed from a realized
sample, and the parameters are considered unknown quantities, described as probability
distributions (Bernardo, 2003).
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Bayesian approach considers the parameters as random variables while the Classical ap-
proach considers the parameter as fixed, even though unknown. On the contrary, while
data is fixed in Bayesian, it is a random sample for Frequentist (Lindley, 2000). Table 1.1
summarizes some of the main aspects that differentiate Bayesian and Classical statistics.
Topics Classic Bayesian
Probability Limit of empirical frequencies Subjective belief
Parameter θ is fixed θ is random
Estimation Likelihood based Posterior based
Sources of
information
Data only Data and prior beliefs
Inference
Interpreted in terms of the
long-run behavior of y
Interpreted as probability
statements about θ
Computation Optimization Integration
Uncertainty Often based on asymptotics Exact
Table 1.1. Comparative aspects of the Classic and the Bayesian types of inference: schematic
summarization of the topics discussed in Lindley (2000).
1.4.1 Advantages and disadvantages of Bayesian Statistics
The Bayesian statistics has both advantages and disadvantages in its implementations and
uses.
One of the main advantage of the Bayesian inference is that it is simple in principle and
provides a framework for coherent inference based on the posterior distribution, which
integrates prior beliefs (various sources of information, including constraints) and additional
information (Bernardo, 2003). Bayesian approach obeys to the likelihood principle being
conditional on the observed data (Berger and Wolpert, 1988), and not in the data that were
possible but not observed. As consequence, inference for small samples is always exact.
Bayesian results often have good Classical properties, being Classical analysis a special case
of the Bayesian under a particular prior in some cases (Lindley, 2000).
Because probability is seen as a mean to describe uncertainty on the parameters, Bayesian
inference naturally deals with conditioning, marginalization and decision theory (Bernardo,
2003). Bayesian inference naturally penalizes complex models, but complex models can be
easily constructed using hierarchical modeling (Gelman et al., 2014g). Hierarchical Bayes
deals with multiple testing inherently.
Modern computational techniques facilitate to work with Bayesian models (Gelman et al.,
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2014b). Partly because of the recent developments in simulation science, it is possible to
actually sample (directly or indirectly) from the posterior, to perform inference.
One of the main disadvantages of the Bayesian inference regards the posterior distribution.
Although Bayesian inference provides a simple and well established framework to compute
the posterior, it is often difficult and time-consuming to implement it in practice (Gelman
et al., 2014b). For complicated posteriors, model exploration, assessment and comparison
can be compromised due to analytical and numerical constrains. In this respect, Classical
inference is simpler in standard statistical analysis (Lindley, 2000). Moreover, Bayesian
inference is conditional on the observed data and may not be generalize.
1.5 Exchangeability
A sequence (y1, ..., yn) of random variables is finitely exchangeable if the joint distribution
p(y1, ..., yn) is invariant under any permutation of the indexes of the random variables,
p(y1, ..., yn) = p(y(1), ..., y(n))
for all permutations on the set {1, ..., n} (Bernardo, 1996). An infinite sequence is infinitely
exchangeable if any finite sub sequence is finitely exchangeable (Bernardo, 1996).
The assumption of exchangeability does not mean that the observations are similar, but
instead that there are no information to specifically distinguish any observation of another.
Exchangeable observations cannot be grouped or ordered by principle (Gelman et al., 2014f).
In Bayesian statistics the exchangeability is a typical probabilistic assumption (Bernardo,
1996; Good, 2002).
By definition, independent and identically distributed random variables are exchangeable,
but the contrary is not verified (Good, 2002). Consider the Polya’s urn, containing two
black balls and three white. We know that the probability of any of the ball configurations
is not independent of the last retrieval, but they are exchangeable, because each ball color
configuration has the same probability.
p(1, 1, 0, 0, 0) =
1
10
= p(0, 1, 0, 0, 1)
The standard bi-dimensional normal distribution is a good example of exchangeable vari-
ables: p(x, y) = N(0, 0, 1, 1, ρxy). x and y can be exchanged, obtaining the the same
probabilistic inferences, however both are by definition not independent.
Chapter 2
Bayesian computation
The Bayesian computation provides a framework to obtain meaningful summaries of the
posterior distribution. Chapter 2 presents some of the most currently used simulation
methods in Bayesian Computation (figure 2.1), particularly focusing the iterative Monte
Carlo simulation techniques.
Figure 2.1. Schematic view of the Bayesian computation techniques.
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2.1 Monte Carlo simulation
Approximations to integrals can be carried out by Monte Carlo integration (Gamerman and
Lopes, 2006a). Suppose θ has a density p(θ) and its intended to calculate the quantity
γ = E[h(θ)].
γ = E[h(θ)] =
∫
h(θ)p(θ)dθ
Consider {θ1, ..., θL}, L independent and identically distributed samples from the distribu-
tion p(θ), then the estimator,
γˆ =
1
L
L∑
i=1
h(θi)
converges to E[h(θ)] almost surely as L→∞, by the strong law of large numbers. Naturally,
as L increased, the quality of the approximation increases (Gamerman and Lopes, 2006a).
V [γˆ] =
1
L
V [h(θ)]
In Bayesian inference, p(θ) is the posterior distribution p(θ|y) and thus E[h(θ)] is the poste-
rior mean of h(θ). In order to use the Monte Carlo approximation in Bayesian computation
is only required to sample from the posterior distribution a sample of size L (Gamerman
and Lopes, 2006a). Another facility of the Monte Carlo method is that any other quantity
than the mean, can be similarly estimated, which includes probabilities (integration of the
posterior density over an interval) using empirical proportions, quantiles using empirical
quantiles or second moments (dispersion measures) (Albert, 2009b).
2.2 Markov Chain Monte Carlo
Markov Chain Monte Carlo (MCMC) methods set up a Markov chain whose stationary
distribution is the posterior distribution. These methods are called Monte Carlo because
rely on random draws from the approximate distribution, and Markov chain because samples
are drawn iteratively as a Markov chain (Albert, 2009c).
2.2.1 Gibbs sampling
Suppose we have a collection of k random variables denoted by θ = (θ1, ..., θk). We assume
that the full conditional distributions
{p(θi|θj , j 6= i), i = 1, ..., k}
are available for sampling and that we have some method to generate samples from the
conditional distributions (Gamerman and Lopes, 2006b). It is not required the one dimen-
sional conditional distributions p(θi|θj , j 6= i) to have a close form, but for sampling it is
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necessary to be able to write them up to a normalization constant (Gelman et al., 2014b).
Furthermore, the conditional distribution of one variable given all others is proportional to
the joint distribution (Gamerman and Lopes, 2006b),
p(θi|θ1, ..., θi−1, θi+1, ..., θk) = p(θ1, ..., θk)
p(θ1, ..., θi−1, θi+1, ..., θk)
∝ p(θ1, ..., θk)
The idea behind the Gibbs sampling is very simple and intuitive. The algorithm proceeds
as follows (Gamerman and Lopes, 2006a; MacKay, 2005b):
1. Generate a set of arbitrary starting values (θ01, ..., θ
0
k).
2. Perform random draws from the uni-variate conditional distributions.
• Draw θ11 from p(θ1|θ02, ..., θ0k, y)
• ...
• Draw θ1k from p(θk|θ11, ..., θ1k−1, y)
3. Repeat the process L times.
The last sample would be (θL1 , ..., θ
L
k ).
We are interested in samples from the joint posterior distribution p(θ|y) but Gibbs provide
draws from each of the univariate conditional distributions p(θi|θj , y, i 6= j). It can be proved
that (θl1, ..., θ
l
k) converges in distribution to p(θ1, ..., θk|y) as L → ∞ being the convergence
geometric in t (Gamerman and Lopes, 2006b).
Obtaining the marginal densities can be straightforward, specially if they all belong to the
exponential family. However, in other cases we cannot be able to identified the conditional
of some parameters as a standard distribution, making the sample process impossible. In
these cases any non-iterative sampling algorithms can be used (eg. rejection sampling).
Any valid way of generating samples from θi|y, θ1, ..., θi−1, θi+1, ..., θk will give a legitimate
MCMC algorithm (Gamerman and Lopes, 2006b).
2.2.2 Metropolis-Hastings algorithm
Similar to the Gibbs sampling, the Metropolis-Hastings algorithm is an MCMC method.
Metropolis-Hastings algorithm was firstly developed by Metropolis in 1953, being adapted
for statistical analysis by Hastings in 1970 (Gamerman and Lopes, 2006c).
Suppose we pretend to sample from the posterior distribution p(θ1, ..., θk|y) = p(θ|y). Let θt
be the current parameter vector and p(θ|θt) be a proposal distribution such that p(θa|θb) =
p(θb|θa). The Metropolis algorithm generate random samples as follows (Carlin and Louis,
2009b; Gamerman and Lopes, 2006c):
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Figure 2.2. Gibbs sampling involves estimating a joint probability distribution of two or
more random variables (here with θ1 and θ2), by sampling from conditional distributions.
Based on MacKay (2005b).
1. Draw θ∗ from p(θ|θt), where θt is the current state of the chain.
2. Calculate the acceptance probability
α(θt, θ∗) =
p(θ∗|y)
p(θt|y) =
p(y|θ∗)p(θ∗)
p(y|θt)p(θt)
3. Set θt+1 = θ∗ with probability α, otherwise set θt+1 = θt.
Note that even when a proposal is not accepted, it counts as an iteration and the last value is
repeated as part of the sample (Gelman et al., 2014b). Metropolis algorithm always accepts
when the posterior density of the proposal is higher than the density of the current value,
but also accepts with probability less than 1 when the proposal density is lower (Gamerman
and Lopes, 2006c). Normal distributions or t-student distributions are common choices for
the proposal distribution (Gelman et al., 2014b). One can see that Metropolis algorithm
is a stochastic version of an optimization algorithm, however, the higher or lower ability to
move to places with lower density in the parameter space is critical in exploring the posterior
distribution (which can contain local maxima) (Gamerman and Lopes, 2006c).
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In certain regularity conditions it can be proved that θ(t) converges in distribution to p(θ|y)
(Gamerman and Lopes, 2006c). However, it must be stressed that the sequence θ(t) is not
independent.
A simple, but important generalization of the Metropolis algorithm was provided by Hastings
in 1970 (Carlin and Louis, 2009b). Hastings drops the requirement of symmetry of the
proposal distribution p(θ|θt), and redefines the acceptance ratio as
α(θt, θ∗) = min
{
1,
p(θ∗|y)
p(θt|y)
p(θt|θ∗)
p(θ∗|θt)
}
With this modification, it can be shown that this algorithm converges to the required
posterior distribution for any candidate proposal density p(θ|θt) (Gamerman and Lopes,
2006c).
The proposal distribution can be anyone, but often normal or t-student proposals centered at
the current iterate θt, are used (Gelman et al., 2014b). Asymmetric proposal such as gamma
distributions, may also be used but require a Hastings adjustment. One can use proposal
distributions that does not depend on the current parameter value. These distributions are
known as independent samplers and require a Hastings adjustment (Albert, 2009c).
The Gibbs sampler can be seen as a special case of the Metropolis-Hastings. If the conditional
distribution is used as the proposal distribution, the draws will be always accept (Gelman
et al., 2014b). In the Gibbs sampler the proposal distribution p(θ∗j |θtj , y) is such that θ∗−j =
θt−j , which means that the others components of θ except θj do not change. Given that the
acceptance probability,
α(θ∗, θt) =
p(θ∗|y)p(θt|θ∗)
p(θt|y)p(θ∗|θt)
=
p(θ∗|y)p(θtj |θt−j , y)
p(θt|y)p(θ∗j |θt−j , y)
=
p(θ∗j |θt−j , y)p(θt−j |y)p(θtj |θt−j , y)
p(θtj |θt−j , y)p(θt−j |y)p(θ∗j |θt−j , y)
= 1
A very common approach is to combine the Metropolis-Hastings algorithm with the Gibbs
sampler in building blocks (Gelman et al., 2014b; Gamerman and Lopes, 2006c). The
Metropolis-Hastings steps are used when a particular posterior conditional distribution does
not have a simple form to sample, and Gibbs sampler for the others. The Metropolis-
Hastings can be single-component or blocked depending on the number of parameters to be
sampled. For models with strongly dependent parameter the Metropolis-Hasting algorithm
can be preferred to improve mixing, even though the Gibbs sampler could be implemented
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(Gamerman and Lopes, 2006c). The tradeoff is between improving independence between
iterates in Metropolis-Hastings and sampling from the proper conditionals with 100% of
acceptance probability in Gibbs (Gelman et al., 2014b).
2.3 Hamiltonian Monte Carlo
Hamiltonian Monte Carlo borrows an idea from physics to suppress the local random walk
behavior commonly observed in the Gibbs and Metropolis-Hastings algorithms, thus allowing
the Markov chain to move much more rapidly through the target distribution (Neal, 2011a).
The random walk behavior is particularly limitative in complicated high-dimensional target
distributions (Gelman et al., 2014c).
Let λ be the model parameters vector. For each component λj in the target space, the
Hamiltonian Monte Carlo adds a momentum variable φj . Both λ and φ are updated together
in a new Metropolis algorithm, in which the jumping distribution for λ is largely determined
by φ (Neal, 2011a). Each iteration proceeds via several steps, during which the position
and momentum evolve based on rules imitating the Hamiltonian dynamics (Gelman et al.,
2014c). Hamiltonian Monte Carlos is also called hybrid Monte Carlo because it combines
MCMC and the determinism of the Hamiltonian trajectory.
2.3.1 Momentum distribution
In Hamiltonian Monte Carlo, the posterior distribution is augmented by an independent
distribution p(φ) on the momenta (Gelman et al., 2014b), thus defining a joint distribution,
p(θ, φ|y) = p(φ)p(θ|y)
We simulate from the joint distribution but we are only interested in the simulation of θ
(the position vector). The vector φ has the same dimension as θ and is an auxiliary variable,
introduced to allow the algorithm to move faster through the parameter space (Neal, 2011a).
It is common to give φ a multivariate normal distribution with mean 0 and covariance setted
to a predefined mass matrix M (Gelman et al., 2014b). The mass matrix is so called by
analogy to the physical model of Hamiltonian dynamics (Neal, 2011a). It commonly used a
diagonal mass matrix, with φj ∼ N(0,Mjj) (Gelman et al., 2014b).
2.3.2 Hamiltonian dynamics
The main part of the Hamiltonian Monte Carlo is a simultaneous update of the (θ, φ),
performed by a discrete mimicking of the physical dynamics (Neal, 2011a). One common
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discretized scheme for the Hamiltonian dynamics is the leapfrog method (Gelman et al.,
2014b). Consider M the mass matrix, the covariance of the momentum distribution p(φ)
and , a scaling factor that should be settled considering the number of leapfrog iterates L
on the Hamiltonian dynamics step: L = 1 (Neal, 2011a). The leapfrog discretization of the
Hamiltonian dynamics becomes, {
φ← φ+ 2 d log p(θ|y)dθ
θ ← θ + M−1φ
Lets explore some intuitive ideas about these equations. Suppose the algorithm move toward
an area of low posterior probability. d log p(θ|y)dθ will be negative in this direction, inducing a
decrease in the momentum in the direction of movement. As the leapfrog steps continue to
move into an area of lower density in θ-space, the momentum continues to decrease. A good
property of the leap frog step is that if the iterations continue to move in the direction of
decreasing density, the leapfrog step will slow to zero and then back down or curve around
the dip (Gelman et al., 2014b).
2.3.3 HMC algorithm
Hamiltonian Monte Carlo algorithm uses the last iterated parameter vector θt and a mass
matrix M as input. The Hamiltonian Monte Carlo algorithm comprises 3 main steps
(MacKay, 2005a):
1. The momentum vector φt is updated. Usually, φ ∼ N(0,M)
2. The discrete Hamiltonian dynamics is them performed, involving L leapfrog steps, each
scaled by a factor .
(a) Initial half-step of φ
φ← φ+ 
2
d log p(θ|y)
dθ
(b) L− 1 alternated updates of θ and φ
φ← φ+ d log p(θ|y)
dθ
∧ θ ← θ + M−1φ
(c) Final half-update of φ.
3. The updated parameter and momentum vectors (θ∗, φ∗) are compared with the initial
iterates (θt, φt) by an accept-reject step, calculating the acceptance probability.
α =
p(θ∗|y)p(φ∗)
p(θt|y)p(φt)
Set θt+1 = θ∗ with probability min(α, 1) and reject otherwise, θt+1 = θt.
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2.4 Convergence and Mixing
The major pitfalls in using MCMC methods are convergence and mixing. Convergence is
achieved when the MCMC iterates can be safely thought of as coming from the stationary
posterior distribution (Carlin and Louis, 2009b). Mixing is achieved when independent
MCMC chains cover the same distribution (Carlin and Louis, 2009b).
Achieving convergence and mixing can be difficult: the iterations have not proceeded long
enough and the simulations may be grossly unrepresentative of the target distribution; the
within-sequence correlation can be high making simulation inferences less precise; and the
presence of local maximums, can lead to cover different distributions (Gelman et al., 2014b).
These special problems of iterative simulation are handled by three good practices in infer-
ential simulation:
• Discarding early iteration of the simulation runs
To diminished the influence of the starting values, generally the first half of each
sequence is discarded (Gelman et al., 2014b). Inferences will be based on the assump-
tion that the distribution of the simulated values ψt for large enough t, are close to the
target distribution p(θ|y) (Carlin and Louis, 2009b). The practice of discarding early
iterations in Markov chain simulations is referred as burn-in (Neal, 2011b).
• Dependence of the iteration in each sequences
MCMC iterates are not independent and successive samples are correlated (Gelman
et al., 2014b). Autocorrelation will be reduced by thinning the sequences by keeping
every k-th simulation draw from each sequence {ψi, ψi+k, ψi+2k, ...} (Carlin and Louis,
2009b). In problems with large numbers of parameters, where computer storage is a
problem, it can be useful to skip iterations.
• Multiple sequences with over-dispersed starting values
Most of the recommended approaches to assess convergence of iterative simulation is
based on comparing different simulated sequences, because to evaluate convergence and
mixing, more than one independent sequence are needed (Carlin and Louis, 2009b).
Thus, it becomes a good practice to simulate independent sequences (at least two),
with starting points drawn from an overdispersed distribution (Neal, 2011b).
Visual representation of MCMC chains can be useful informing if the iterates have converged
to its stationary distribution or if they are mixed, i.e. covering the same distribution (figure
2.3). The recommended practice is to combine formal and visual methods to assess the
convergence of the MCMC chains (Gelman et al., 2014b; Neal, 2011b).
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Figure 2.3. Convergence and mixing of two MCMC chains. In the left plot, while
both sequences look stable, their non-overlapping suggest they have not converged
to a common distribution. In the right plot, the two sequences cover a common
distribution but none of sequences are stationary. Based on (Gelman et al., 2014b)
2.4.1 Scale reduction factor
One of the most common methods for monitoring MCMC convergence is the potential scale
reduction factor (Rˆ) proposed by Gelman and Rubin (1992). Multiple MCMC sequences
are started from overdispersed initial points and compared. Rˆ assess the convergence of
the chains comparing the variance and mean of each chain to the variance and mean of the
combined chain (Gelman and Rubin, 1992).
Consider m parallel chains with 2n samples each. Only the last n better converged samples
from each chain are used. The between-chain variance and pooled within-chain variance are
defined as, respectively
B
n
=
1
m− 1
m∑
j=1
(ψ¯j. − ψ¯..)2 W = 1
m(n− 1)
m∑
j=1
n∑
i=1
(ψji − ψ¯j.)2
where ψ¯j. is the mean of the samples in chain j and ψ¯.. is the mean of the combined chains.
Finally an estimate of Rˆ is obtained by dividing the pooled posterior variance with the
pooled within chain variance,
Rˆ =
√
Vˆ
W
where Vˆ =
n− 1
n
W +
(
1 +
1
m
)
B
n
If the chains have converged, Rˆ is close to 1, which makes it a useful indicator of convergence
(Gelman and Rubin, 1992). Rˆ has some limitations (Venna et al., 2003): the chains might
not have covered the state space and might discover new areas of high probability; it does not
take higher-order moments into account (only the mean and variance); and it is applicable
to only one variable at a time.
Chapter 3
CNV detection and identification
Copy number variations (CNVs) are genetic structural alterations of different types and
sizes. In this thesis we focused the problem of detecting and identifying exonic CNVs.
Exons corresponds to the portions of a gene that code for a protein (figure 3.1). Chapter
3 introduces some biological aspects of the CNV detection and identification problem and
additionally discusses some aspects of the data structure.
Figure 3.1. Schematic view of exonic structural alterations. A normal individual
is compared with two copy number variants (duplication and deletion) for the exonic
regions of the gene A.
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3.1 Copy number variations
During the last years geneticists have been characterizing hundreds of repetitive regions
in DNA (Redon et al., 2006), contributing to the idea that structural-level alterations
are as important as the sequence-level genomic diversity, to understand the variability
among individuals and populations (Stankiewicz and Lupski, 2010). These repetitive regions
are denominated CNVs (copy number variations) and represents an imbalance between
two genomes from one species, affecting segments of DNA ranging from one kilobase to
several megabases in size (Feuk et al., 2006). CNVs account for approximately 12% of the
human genomic DNA and are caused by structural rearrangements: deletions, duplications,
triplications, insertions, or translocations can result in CNVs (Redon et al., 2006; Stankiewicz
and Lupski, 2010).
Gene-specific CNVs have been associated with susceptibility and resistance to diseases.
CCL3L1 is a potent human immunodeficiency virus (HIV) suppressive chemokine and was
shown that lower CCL3L1 copy numbers were associated with markedly enhanced HIV/acquired
immunodeficiency syndrome susceptibility (Gonzalez et al., 2005). The development of
systemic autoimmunity is also associated with low FCGR3B copy numbers (Fanciulli et al.,
2007). Confirmed de novo CNVs were significantly associated with more complex diseases,
as autism (Sebat et al., 2007).
Next-generation sequencing technique is facilitating an increase in the efficiency and reso-
lution of CNVs detection, becoming the most popular strategy (Metzker, 2010). CNVs are
identified in two steps (figure 3.2): a sequencing step, in which the sample DNA is shredded
into small fragments that are partially sequenced (reads); and an assembly step, in which the
reads are aligned considering a reference sequence. In comparison with alternative methods,
next-generating sequencing approach has the advantage of having higher resolution, more
accurate estimation of copy numbers and higher capacity to identify novel CNVs (Alkan
et al., 2011; Meyerson et al., 2010).
3.1.1 Coverage readings
A raw dataset from next-generation sequencing procedures includes the coverage readings
and the respective genomic position. The coverage readings constitute the number of times
a specific genomic site in the reference genome is covered by the reads produced by next-
generation sequencing.
Given the biological and medical importance of CNVs, it is mandatory to develop proba-
bilistic models that easily enable the detection CNVs from next-generation sequencing data.
While other models have been developed to detect CNVs in a genomic scale (Sepu´lveda et al.
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Figure 3.2. A schematic next-generation sequencing procedure
to identify CNVs. Genomic DNA is shredded into fragments of
manageable size. These fragments are partially sequenced as reads.
Reads are subsequently aligned with a reference genome. The number
of times a particular genomic site is covered by the reads constitute the
coverage readings.
(2013) and Zhao et al. (2013) for a deep revision), an inferential approach that assists in the
identification of CNVs in the exonic regions of genes, is in need. Exons are the regions of
protein-coding genes that contribute to the protein (i.e. which are transcribed and translated
into proteins; figure 3.1).
3.2 Objectives
The main objective of this thesis is to create an inferential model which permits to detect and
identify CNVs on the exonic regions of genes using the next-generation sequencing coverage
readings. In particular, it is intended:
• Objective 1. To present a suitable strategy to deal with the coverage noise (i.e. the
coverage variations that are not related with the presence of exonic CNVs).
• Objective 2. To construct a probabilistic model for the exonic coverage ratio model-
ing.
• Objective 3. To create an inferential framework to detect the presence of CNVs in
protein-coding genes, in a early phase of the CNVs analysis.
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• Objective 4. To develop an inferential framework to identify CNVs, when a potential
altered-gene is detected. The identification of CNVs includes determining the type of
exonic CNVs (deletion, duplication, etc.).
3.3 Data structure
The analysis of CNVs is highly relative − what can be considered a duplication of a DNA
fragment, can be considered a deletion in the fragment that was used to compare. Thus, the
analysis of the exonic structure of genes may only be implemented using an exonic structure
that we determine to be the standard. A standard exonic structure can be the most common
in the analyzed population.
In addition, the comparison of coverage profiles indicate similar qualitative behaviors, sug-
gesting they should be related up to a deformational constant (figure 3.3). Individual
coverage readings can differ not only by the the presence of CNVs, but also by the reaction
conditions of the next-generation sequencing (quantity of reagents and DNA in the sample,
primer scheme, etc.), suggesting that some of the observed variability may be due to the
experimental procedure.
Figure 3.3. Comparison of two coverage profiles for the 10-th exon of the BRCA1 gene. The
coverage readings peaks correspond to overlapping regions resulting from the next-generation
sequencing and not to CNVs. As can be observed, these regions are common in both the
coverage profiles.
It would be recommended to perform a data standardization which would minimize the effect
of the next-generation sequencing reaction conditions, evidencing the unexpected features of
the coverage readings. Consider that xk is the coverage reading of the k-th genomic position.
A longitudinal standardization of the individual coverage (expression 3.1) readings appears
attractive but suffers from some problematic aspects.
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xk − x¯..
s..
(3.1)
The longitudinal standardization can be highly biased by the noise introduced by the
experimental variables. In addition, the longitudinal correction is highly sensitive to extreme
observations, which can be the case when CNVs are present in the analysis. Thus, the
estimated grouped coverage ratio mean and variance (biased by the CNV coverage readings)
may dilute statistical signatures of CNVs. Finally, the longitudinal standardization do not
allow multi-individual comparison analysis. CNV detection would be dependent on the mean
and dimension of the case study individual coverage, being meaningless to compare statistics
from different individuals.
3.3.1 Coverage ratio
We advance a standardization of the coverage readings that takes into account a reference
coverage profile (equation 3.2). Consider that Cmk is the observed coverage reading of the
m-th individual in the k-th genomic position. Consider also the reference C0 and the case
study C1 observed coverage readings, the coverage ratio is defined as:
yk =
C1k
E[C1k |C0k ]
=
C1k
f(C0k)
− 1 (3.2)
E[C1k |C0k ] constitutes the expected case study individual coverage when a certain value of
the reference coverage C0k is observed. This factor eliminates the heterogeneity that depend
on the experimental design/conditions and which are not associated with the presence of
CNVs. In addition, the coverage ratio has a direct interpretation in the problem of CNVs
detection and identification: exonic coverage ratios near to 0 would suggest the absence
of a CNV, while coverage ratios near to 1 can be supportive of an additional copy (both
conclusions were made taking in consideration the reference coverage). The main difficulty
in calculating the coverage ratio is the determination of E[C1k |C0k ], which must be analyzed
and computed for each gene in study.
Chapter 4
Hierarchical Bayesian model
Consider the CNV detection problem of comparing the means of the exonic coverage ratios
θj of a group of J exons. Exons are discrete categories of a particular gene, in which
we observed a random sample of nj values of yij coverage ratios (figure 4.1). Chapter 4
presents and discusses the Bayesian approach that is used to model the CNV detection and
identification problem.
Figure 4.1. Schematic representation of the statistical problem underlying the detection and identification
of CNVs.
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4.1 Classical solution
The CNV detection problem can be formalized as:
θ1 = θ2 = ... = θJ
The statistical problem consists in compare the differences among J group means and can be
solved using a classical analysis of variance (ANOVA). The idea behind ANOVA is simple: if
the J group means appear significantly variable we chose separate sample means (θˆj = y¯.j);
alternatively, if the variance between the group means is not significantly greater than the
exon-specific variability, we should used the pooled mean estimate (θˆ = y¯..).
ANOVA methodology presents some assumption that makes it fragile in applications: one is
the need of many observations per group and the other is its philosophy. ANOVA establishes,
as its name implies, not a comparison of means but an analysis of variance. Therefore, even
if ANOVA was useful determining the existence of at least one different exonic coverage ratio
mean, later identification would be difficult. We could implement the Tuckey tests, which
perform paired comparisons of the exon means, but this analysis requires a strict p-value
adjustment and do not allow CNV-type characterization. Moreover, it is very common to
find logic inconsistencies in the Tuckey tests.
We could also use, alternatively, a non-parametric approach, but the difficulty of identify
CNVs still remains. Classical methods have all in common a set of limitative aspects where
the Bayesian framework is a clear advantage:
• both gene and exon-level inferences must be integrated for the detection and identifi-
cation phases of CNVs
• the exon inferences are meant to be individual-dependent (and not populational), as
it is proper of diagnosis analysis
• the parameters uncertainty must be used to performed inference and their accuracy
and precision should be accounted to support conclusions.
4.2 Hierarchical model
The problem of the CNV detection involves multiple parameters (θ and possibly their
variances) which represent descriptive parameters of the same genomic unit, the gene, thus
implying that a joint probability model should reflect they dependence.
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Naturally, such a problem should be modeled hierarchically, with the coverage ratios modeled
conditionally on certain parameters, known as hyperparameters: φ. The exonic coverage
ratio means θj are considered to be random samples from the hyperparameters distribution.
4.2.1 Exchangeability in hierarchical models
If no other information exists to distinguish any of the θj apart from the data y, and no
ordering or grouping of the parameters can be made, we must assume symmetry among the
parameters in their prior distribution (Gelman et al., 2014f). The symmetry is represented
probabilistically by exchangeability, being a necessary condition to build hierarchical mod-
els. By definition, the coverage ratio means are exchangeable in their joint distribution if
p(θ1, ..., θJ) is invariant to permutations of indexes (1, ..., J) (Bernardo, 1996). In practice,
ignorance implies exchangeability and we do not have reasons to believed that a particular
exonic θj would have differentiated coverage ratio mean − we have no information to
distinguish or group the J exons.
The simplest form of an exchangeable distribution considers each of the θj as independent
samples from a prior distribution governed by the same unknown hyperparameter vector φ
(Gelman et al., 2014f),
p(θ|φ) =
∏
j
p(θj |φ)
4.2.2 Hyperparameters
The hyperparameters (φ) distribution is not known and thus has its own prior distribution
p(φ). The joint prior distribution is
p(φ, θ) = p(φ)p(θ|φ)
and the joint posterior distribution is
p(φ, θ|y) ∝ p(φ, θ)p(y|θ, φ)
= p(φ)p(θ|φ)p(y|θ)
with the latter simplification holding because the hyperparameters φ affect y only though
θ and thus, the likelihood p(y|φ, θ) depends only on θ (Gelman et al., 2014f). In order to
create a joint probability model for (θ, φ) we must assign a prior distribution to φ. Usually,
if little is known about φ we can assign a diffuse prior distribution, choice that will require
to check that the resulting posterior distribution is proper (Gelman et al., 2014f).
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4.3 Robust hierarchical model
To model the exonic coverage ratios θj , we implemented a robust hierarchical Bayesian
model. The robust hierarchical approach assigns a t-student distribution (Gelman et al.,
2014d), which is a heavy-tailed distribution and allows for extra dispersion in the data (a
common limitation of the standard normal models). Before considering the probabilistic
aspects of the model, let us first introduce the model parameters in the context of CNV
detection and identification problem (figure 4.2). µ represents the mean of exonic coverage
ratio means. τ is the scale of the exonic coverage ratio means. µ and τ can be useful
parameters, informing whether a CNV is likely to exist in the group of exons, characterizing
the gene-specific behavior of the coverage ratio. θj represent the j-th exon coverage ratio
mean and Vj is the j-th exon coverage ratio variance. These parameters are as many as the
number of exons in the case study gene and characterize the exon-specific behavior of the
coverage ratio, being useful determining the probability of a specific exon to possess a CNV.
Figure 4.2. Structure of the hierarchical model for the CNV detection and
identification problem.
We pretend to leave our model as general as possible for any gene we might want to study,
thus we expect to accommodate well behaved coverage ratios but also, occasional extreme
observations, which the presence of CNVs would probably promote. We opt for a robust
t-student hierarchical approach to model the exon-specific coverage means: p(θ) = tν(µ, τ
2).
p(θ) =
Γ
(
ν+1
2
)
Γ
(
ν
2
)√
νpiτ
[
1 +
1
ν
(
θ − µ
τ
)2]− ν+12
The t distribution is characterized by a center µ, a scale τ and a degree of freedom parameter
ν. ν is not an interpretable parameter on the biological problem of the CNV detection and
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identification, however it can be very useful controlling the tail behavior of the t-distribution,
which is, the propensity for outlier events in the group of the exonic coverage ratio means.
The quantitative behavior of ν can accommodate a diverse fashion of possible probabilistic
distributions for θ: ν = 1 represents the particular case of a Cauchy distribution and as
ν → ∞, the t-student distribution approaches the normal distribution, which is simply the
normal hierarchical model.
Consider J independent exons, with exon j estimating the parameters θj and Vj from nj in-
dependent data points, the j-th exon coverage ratio values yij . In order to perform Bayesian
inference on the hierarchical model we must determine their posterior full probability model.
p(θ, V, µ, τ, ν|y) ∝ p(θ, V, µ, τ, ν)p(y|θ, V, µ, τ, ν) (4.1)
4.3.1 Prior distribution
The prior distribution must be set for the model parameters and hyperparameters. The
joint probability distribution can be usefully decomposed in the three terms.
p(θ, V, µ, τ, ν) ∝ p(θ|V, µ, τ, ν)p(V |µ, τ, ν)p(µ, τ, ν)
For the hyperparameters a uniform prior is assigned. Indeed, none or almost none informa-
tion about µ, τ and ν are available prior the realization of the coverage measurements that
would worth an informative prior. In addition, the hyperparameters are not observed in the
experience, which compromise advancing distributional considerations.
The assumption behind the t-model, which considers that θj |ν, τ, µ follows a tν(µ, τ2) dis-
tribution can be alternatively thought as a mixture of normal distributions with a common
mean and variances following a scaled inverse-χ2 distribution. Thus, the conditional distri-
butions of the t-student model define the priors of the exonic parameters.
θ | V, µ ∼ N(µ, V ) (4.2)
V | τ, ν ∼ Inv−χ2 (ν, τ2) (4.3)
A scaled inverse-χ2 distribution is a special case of the inverse gamma distribution with shape
and scale parameters equals to ν2 and
ν
2τ
2 respectively. If V follows a scaled inverse-χ2(ν, τ2)
then,
p(V ) =
(
ν
2
) ν
2
Γ
(
ν
2
)τνV −( ν2 +1) exp{−ντ2
2V
}
V > 0
To obtain a simulation draw from a scaled inverse-χ2(ν, τ2) distribution, we first draw Y
from the χ2ν and then we compute X =
ντ2
Y . This property is useful for computational
implementations.
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4.3.2 Likelihood
The coverage ratio are considered to be normally distributed, and thus the likelihood of each
i-th observation in the j-th exon, yij follows N(θj , Vj).
p(y.j |θj , Vj) ∝ V −
nj
2
j exp
{
− 1
2Vj
∑
i
(yij − θj)2
}
∝ V −
nj
2
j exp
{
− 1
2Vj
[(nj − 1)s2.j + nj(y¯.j − θj)2]
}
The likelihood can be written in terms of the sufficient statistics y¯.j =
1
nj
∑
i yij and s
2
.j =
1
nj−1
∑
i(yij − y¯.j)2.
Since we have no prior information to distinguished exons, the between exon observations
should be considered exchangeable. Thus, the total likelihood becomes the product of the J
exon-specific normal densities.
p(y|θ, V ) =
∏
j
p (y.j |θj , Vj) (4.4)
4.3.3 Posterior distribution
Using the prior and the likelihood (equations 4.2 to 4.4) we obtain the posterior distribution
using the Bayes rule (equation 4.1).
p(θ, V, µ, τ, ν | y) ∝ N(θ | µ, V )Inv−χ2 (V | ν, τ)
∏
j
p (y.j |θj , Vj)
∝
(
ν
2
)Jν/2
Γ
(
ν
2
)J τJν exp
−∑
j
1
2Vj
[ντ2 + (θj − µ)2 + (nj − 1)s2.j + nj(y¯.j − θj)2]

∏
j
[
V
−
(
−nj+3+ν
2
)
j
]
(4.5)
4.3.4 Posterior conditional distributions
The posterior distribution (equation 4.5) is a complex expression, however their full condi-
tional posterior distributions are, except for ν, known cases.
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• Conditional posterior distribution of µ
Conditional on the data y and the other parameters of the model, information about
µ is supplied by θj , each with its own variance Vj . Combining with the uniform prior
distribution on µ yields,
p(µ|., y) ∝ exp
−12 ∑
j
(θj − µ)2
Vj

∝ exp
−12
∑
j
1
Vj
µ− ∑j θjVj∑
j
1
Vj
2
= N
(∑
j
1
Vj
θj∑
j
1
Vj
,
1∑
j
1
Vj
)
(4.6)
• Conditional posterior distribution of τ2
Conditionally on the data y and the other parameters of the model, all the information
about τ comes from the variances Vj and ν. The posterior is a gamma distribution.
p(τ2|., y) ∝ τJν exp
−ντ22 ∑
j
1
Vj

= Gamma
Jν
2
+ 1,
ν
2
∑
j
1
Vj
 (4.7)
• Conditional posterior distribution of θj
In the joint posterior density the factors that involve θj are the N(µ, τ
2) prior distri-
bution and the normal likelihood. Conditional on the hyperparameters and the vector
of exon variances V , information about θj is supplied by µ and the nj coverage ratio
observations yij .
p(θj |., y) ∝ exp
{
− 1
2Vj
[(θj − µ)2 + nj(y¯.j − θj)2]
}
∝ exp
{
−nj + 1
2Vj
(
θj − µ+ y¯.jnj
nj + 1
)2}
= N
(
µ+ y¯.jnj
nj + 1
,
Vj
nj + 1
)
(4.8)
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• Conditional posterior distribution of Vj
Conditional on the data y and the other parameters of the model and with a normal
likelihood, each Vj has a scaled inverse-χ
2 posterior distribution.
p(Vj |., y) ∝ Vj−
nj+3+ν
2 exp
{
− 1
2Vj
[
ντ2 + (θj − µ)2 + (nj − 1)s2.j + nj(y¯.j − θj)2
]}
= Inv−χ2
(
nj + 1 + ν,
ντ2 + (nj − 1)s2.j + (θj − µ)2 + nj(y¯.j − θj)2
nj + 1 + ν
)
=
ντ2 + (θj − µ)2 + (nj − 1)s2.j + nj(y¯.j − θj)2
χ2nj+1+ν
(4.9)
• Conditional posterior distribution of ν
The conditional distribution of ν does not take a simple form.
p(ν|., y) ∝
(
ν
2
)Jν/2
Γ
(
ν
2
)J τJν exp
−ντ22 ∑
j
1
Vj
∏
j
[
V
−
(
−nj+3+ν
2
)
j
]
(4.10)
4.3.5 Gradient Vector
For the Hamiltonian Monte Carlo algorithm we need the gradient of the log posterior density
(table 4.1). Within the robust hierarchical model the operations are easily performed. Let
λ = (µ, τ, θ, V, ν).
log p(λ|y) =Jν
2
log(ν/2)− J log Γ(ν/2) + Jν log τ
−
∑
j
1
2Vj
[ντ2 + (θj − µ)2 + (nj − 1)s2.j + nj(y¯j − θj)2]
− 1
2
∑
j
(nj + 3 + ν) log Vj
An Hamiltonian Monte Carlo algorithm with constrained parameters can lead the trajectory
outside the boundary, thus wasting some iterations. We have three positive real parameters:
τ , Vj and ν. One remedy is to transform the space to be unconstrained. In this case, the
simplest way to handle the constraint τ > 0 is to transform to log τ .
This requires that the posterior must be multiplied by the Jacobian τ , which means adding
the log τ to the log posterior. The gradient also changes, considering the adding term on
the log posterior and the necessary subsequent multiplication by the Jacobian. We proceed
to the Vj and ν log-transformation as we explained for τ .
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Parameter Component Expression
µ ∂ log p(λ|y)
∂µ
∑
j
1
Vj
(θj − µ)
τ ∂ log p(λ|y)
∂ log τ
Jν − ντ2∑j 1Vj + 1
θj
∂ log p(λ|y)
∂θj
1
Vj
[µ+ nj y¯.j − (1 + nj)θj ]
Vj
∂ log p(λ|y)
∂ log Vj
1
2Vj
[ντ2 + (θj − µ)2 + (nj − 1)s2.j + nj(y¯j − θj)2]− nj+3+ν2 + 1
ν ∂ log p(λ|y)
∂ log ν
Jν
2
(log ν/2 + 1)− Jν
2
log Γ(ν/2)
dν/2
+ Jν log τ − ν
2
∑
j log Vj − ντ
2
2
∑
j
1
Vj
+ 1
Table 4.1. The gradient vector components for the Hamiltonian Monte Carlo algorithm. The τ , V and ν
parameters were log-transformed.
Considering the log-transformations of the τ , V and ν parameters, the position vector for
the Hamiltonian Monte Carlo becomes λ = (µ, log τ, θ, log V, log ν) and the log posterior
distribution,
log p(λ|y) =Jν
2
log(ν/2)− J log Γ(ν/2) + Jν log τ
− 1
2
∑
j
1
Vj
[ντ2 + (θj − µ)2 + (nj − 1)s2.j + nj(y¯j − θj)2]
1
2
∑
j
(nj + 3 + ν) log Vj
+ log τ +
∑
j
log Vj + log ν
4.4 Computational implementation
The hierarchical robust model developed here was implemented in the R language. In a first
phase the algorithm extracts the next-generation sequencing data for the desired genomic
coordinates. The files with the coverage readings are of the .bam type and the genomic
coordinates are of the .bai type. To extract the coverage readings the R package rbamtools
was used (Li et al., 2009).
After the extraction of the data it is implemented the Hierarchical Bayes. Taking advantage
of the marginal posteriors of each parameter it was constructed an iterative MCMC scheme.
For those parameters which possess well know posterior marginal distributions (i.e. µ, τ2,
θ and V , equations 4.6 to 4.9) the Gibbs sampler was used. Because the parameter ν has
a complex and unknown posterior marginal (equation 4.10) we have used, alternatively,
the Metropolis-Hastings algorithm. The Gibbs and the Metropolis Hastings techniques
were combined in building-blocks, that proceed iteratively. A schematic outline of the
computational implementation and the R code are represented in the Appendix A.
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rnu <- function(nu,tau,V,snu) {
inu <- rnorm(1,1/nu,snu)
if (inu <= 0 | inu >1) {
jp <- 0
} else {
nus <- 1/inu
r <- exp( nus*( J*log(nus/2)/2 + J*log(tau) -
sum(log(V))/2 - tau*tau*sum(1/V)/2 ) - J*lgamma(nus/2) -
nu*( J*log(nu /2)/2 + J*log(tau) -
sum(log(V))/2 - tau*tau*sum(1/V)/2 ) + J*lgamma(nu /2) )
if (runif(1) < r) {
nu <- nus
}
jp <- min(r,1)
}
return(c(nu,jp))
}
Figure 4.3. Metropolis-Hastings algorithm implemented in R for simulating the ν parameter on the
Hierarchical Bayesian robust model.
4.4.1 Metropolis-Hastings step for 1/ν
Simulating 1/ν using the Metropolis-Hastings algorithm requires the definition of a proposal
distribution. We used the normal density, with mean in the last sampled iterate and standard
deviation snu (figure 4.3).
The standard deviation or the dimension parameter of the proposal distribution must be
defined carefully. In one hand, it must be considered that lower values of snu promote
intra-chain correlation, leading to the undesirable random walk behavior of ν iterates (and
also on the dependent parameters, as τ and V ). In the other hand, if snu is too high can
lead to higher rates of rejection which decrease the efficiency of the algorithm. We proceed
with some simulations and conclude that snu between 0.10 and 0.08 guarantees a mean
acceptance probability of approximately 44%, the recommended acceptance probability for
one dimension (Gelman et al., 2014b).
4.4.2 Hamiltonian Monte Carlo
To avoid the slow exploration of the parameters space in the posterior distribution (as were
common to the ν, τ2 and V parameters) we implemented the Hamiltonian Monte Carlo
algorithm in conjunction with the Gibbs and the Metropolis Hastings building-blocks.
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hmc <- function(lambda,M,epson,mj,s2j,nj){
L <- floor(1/epson)-1
D <- length(lambda)
#RANDOM MOMENTUM
psi <- rnorm(D,0,sqrt(M))
lambdai <- lambda
lposti <- lpost(lambda,mj,s2j,nj) - sum(psi*psi/M)/2
#LEAPFROG STEP
psi <- psi + epson*lgrad(lambda,mj,s2j,nj)/2
for (i in 2:(L-1)) {
lambda <- lambda + epson*psi/M
psi <- psi + epson*lgrad(lambda,mj,s2j,nj)
}
psi <- psi + epson*lgrad(lambda,mj,s2j,nj)/2
#METROPOLIS STEP
r <- exp(lpost(lambda,mj,s2j,nj) - sum(psi*psi/M)/2 - lposti)
if (is.na(r) == T) { r <- 0 }
if ( runif(1) <= min(1,r) ) {
return(c(1,lambda))
} else {
return(0)
}
}
Figure 4.4. Hamiltonian Monte Carlo algorithm implemented in R. lgrad and lpost correspond to the
gradient and log-posterior functions respectively.
The Hamiltonian Monte Carlo algorithm uses as input the  value, the M mass matrix (figure
4.4) and the log-posterior gradient vector (table 4.1). The  value is used to calculate the
necessary leapfrog iterates, considering the condition L = 1. The M mass matrix is defined
by default as a diagonal matrix, with diagonal vector m = 1.
Chapter 5
Case study: BRCA1 and BRCA2
genes
Chapter 5 includes a discussed application of the robust hierarchical Bayesian model to detect
and identify CNVs in the BRCA1 and BRCA2 genes. BRCAs are protein-coding-genes with
a known exonic structures of 23 and 26 expressed exons (figure 5.1).
Figure 5.1. Schematic view of the BRCA1 and BRCA2 genes in the human genome. Exons are
in relative sizes. Retrieved from Fackenthal and Olopade (2007).
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5.1 BRCA1 and BRCA2 genes
BRCA1 and BRCA2 genes encode proteins playing a role on the repair of the genetic material.
Mutation or structural alterations on these genes may compromise the proper repair of the
altered DNA which frequently leads cells from growing and dividing too rapidly or in an
uncontrolled way (Fackenthal and Olopade, 2007).
Mutations on BRCA1 and BRCA2 genes increase woman’s risk to develop breast and ovarian
cancer (Easton, 1999; Pal et al., 2005). Studies have shown that CNVs in the BRCA1 and
BRCA2 genes could also lead to breast and ovarian cancer development (Krepischi et al.,
2012; Kuusisto et al., 2013).
BRCA1 and BRCA2 genes are present in different regions of the Human genome (table
5.1). BRCA1 is located on the chromosome 17, in the 41 197 694 to 41 277 287 genomic
coordinates and comprising 22 expressed exons. BRCA2 is located on the chromosome 13,
between the 32 890 558 and 32 973 809 genomic coordinates and possess 26 expressed exons.
In both genes the exon 1 is not expressed (table 5.1 and figure 5.1).
5.1.1 Experimental design
We analyze 10 individuals for the BRCA1 and BRCA2 genes by the next-generation sequenc-
ing technique under similar reaction conditions. The BRCA1 and BRCA2 exonic coverage
readings were assessed for all the individuals, and the individual 10 was used as reference, to
calculate the other individual’s coverage ratio. Individual 10 was chosen for having a typical
genetic structure for both the BRCA1 and BRCA2 genes. Individual 7 and 9 possess exonic
CNVs determined by alternative methodologies:
• Individual 7, BRCA2, exon 20
• Individual 9, BRCA1, exon 16
• Individual 9, BRCA2, exons 19 and 20
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Gene Genomic coordinates Gene Genomic coordinates
BRCA1 41197694 41277287 BRCA2 32890558 32973809
exon 2 41276034 41276113 exon 2 32890598 32890664
exon 3 41267743 41267796 exon 3 32893214 32893462
exon 4 41258473 41258550 exon 4 32899213 32899321
exon 5 41256885 41256973 exon 5 32900238 32900287
exon 6 41256139 41256278 exon 6 32900379 32900419
exon 7 41251792 41251897 exon 7 32900636 32900750
exon 8 41249261 41249306 exon 8 32903580 32903629
exon 9 41247863 41247939 exon 9 32905056 32905167
exon 10 41243452 41246877 exon 10 32906409 32907524
exon 11 41242961 41243049 exon 11 32910402 32915333
exon 12 41234421 41234592 exon 12 32918695 32918790
exon 13 41228505 41228631 exon 13 32920964 32921033
exon 14 41226348 41226538 exon 14 32928998 32929425
exon 15 41222945 41223255 exon 15 32930565 32930746
exon 16 41219625 41219712 exon 16 32931879 32932066
exon 17 41215891 41215968 exon 17 32936660 32936830
exon 18 41215350 41215390 exon 18 32937316 32937670
exon 19 41209069 41209152 exon 19 32944539 32944694
exon 20 41203080 41203134 exon 20 32945093 32945237
exon 21 41201138 41201211 exon 21 32950807 32950928
exon 22 41199660 41199720 exon 22 32953454 32953652
exon 23 41197695 41197819 exon 23 32953887 32954050
exon 24 32954144 32954282
exon 25 32968826 32969070
exon 26 32971035 32971181
exon 27 32972299 32972907
Table 5.1. Genomic coordinates for BRCA1 and BRCA2 genes exonic regions.
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5.2 Reference coverage transformation
We propose the use of a reference coverage readings to standardize the case study individual
coverage readings, using the expected case study coverage given the standard coverage:
f(C0) = E[C1|C0] (equation 3.2). We firstly analyzed the type of relationship between the
coverages, and we found it clearly linear for both the BRCA1 and BRCA2 genes (figure 5.2).
In addition, we consider that the genomic regions uncovered by the experimental procedure
should return 0 coverage in both, the case study and the reference individuals, thus implying
that the linear relationship between coverages should be of the type f(C0) = aC0.
We used the minimum mean square error estimator to calculate the value of a. We obtained,
aˆ =
∑
iC
0
i C
1
i∑
i(C
0
i )
2
In normal applications we do not know whether one or more CNVs are present in the
case study individual, which naturally, could interfere in the computation of aˆ. During the
standardization phase, we would want the potential CNV coverage readings interfere as little
as possible, so they can be more easily identified later, using a proper statistical analysis.
Using the coverage readings from the individuals which possess exonic CNVs (individuals 7
and 9), we compare the estimates of aˆ with and without the coverage points corresponding
to the altered-exons (figure 5.2). We conclude that the presence of coverage readings from
exonic CNVs were of minimal importance when computing aˆ, and by consequence, when
computing the coverage ratios.
We proceed thus without performing any correction to a.
5.3 MCMC output analysis
We proceed with the MCMC algorithm for 2 chains and 30 000 iterations. We thin the
resulting chain keeping every 20th iterate, thus 1500 iterates were kept for further analysis.
The first 500 iterates were burned-in.
The convergence and mixing of the MCMC iterates was evaluated using both, the potential
scale reduction index (Rˆ) and visual inspection (Gelman and Rubin, 1992). The Rˆ was
estimated for all the parameters of the model and for each iterate, but the max{Rˆ} was
assessed to globally determined the convergence and mixing of each chain. The condition
max{Rˆ} < 1.01 was used and verified for all runs. Visual inspection of the MCMC chains was
employed via trace plots (parameter draw vs. iterate number) and autocorrelation plots to
additionally validate convergence (within chain behavior), mixing (between chain behavior)
and independence of the iterates.
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Figure 5.2. Comparison of the linear estimates of E[C1|C0], the expected case study coverage
given the standard coverage, by accounting (blue line, slope a1) and not accounting (red line, slope
a2) with the exonic CNVs.
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The converged, well mixed and independent MCMC iterates constitute random draws from
the posterior distribution and were used to estimate the posterior model parameters. Here
we have used the quadratic loss criteria (i.e. the mean) to provide an point estimate of the
model parameters.
5.4 Model assessment
The model assessment is necessary to validate the parametric assumptions that were made
when the hierarchical robust model was constructed:
• The coverage ratio is normally distributed: yij ∼ N(θj , Vj)
• The coverage ratio means are t-student distributed: θ ∼ tν(µ, τ2)
• A uniform prior distribution was assigned to the hyperparameters.
5.4.1 Sensitivity analysis
The hyperparameters of the hierarchical Bayesian robust model were considered as having
a uniform prior distribution: p(µ, τ2, 1/ν) ∝ 1. The uniform prior is a non-informative prior
and it is particularly suited for this case study as neither we have previous information
on the hyperparameters, nor they are directly observed during the experience to validate a
potential informative prior.
It is thus essential to analyze the marginal posterior distributions of the hyperparameters in
order to check if the data information was properly captured. We conclude that the marginal
posteriors of the hyperparameters do give reasonable posterior information (figure 5.3): they
all posses non-flat distributional features with a clear mode. Similar results were observed
in others individuals/genes.
Other aspect to take in consideration is the propriety of the posterior distribution. The use
of a uniform prior distribution on the parameters with infinite support (µ and τ) leads to
improper priors. However, as we already have shown (equations 4.6 and 4.7) the conditional
posterior distributions of µ and τ are proper.
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Figure 5.3. Histograms of the marginal posterior distributions of the hyperparameters µ, τ and
1/ν, based on converged, mixed and independent MCMC draws. This is a particular case were the
presence of CNVs have been reported in the 19th and 20th exons.
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5.4.2 Normal likelihood
The likelihood was assumed to be normal distributed: yij ∼ N(θj , Vj). To verify this
assumption we proceed with the normalization of the coverage ratios
zij =
yij − θj√
Vj
considering the posterior estimates of the hierarchical robust model parameters. The normal-
ized observations were used to calculate four summary statistics: mean, standard deviation,
skewness and kurtosis. The observed summary statistics were compared with the values we
would expect to obtain on a standard normal distribution.
The analysis of the expected and the observed summary statistics lead to the conclusion that
the observed data deviates from the normal distributed data only for the third and forth
order moments (figure 5.4). The model parameters (θ and V ) satisfactory describe the mean
and the variability of the exonic coverage ratios. In some particular cases, the variance of
the normalized coverage ratios is out of the expected 95% intervals.
V [zij ] = V
[
yij − θj√
Vj
]
=
V [yij ]
Vj
For those exons we verify that V [zij ] < 1, from which we conclude that V [yij ] < Vj ,
suggesting that some Vj are being overestimated. For this particular analysis we have used
the quadratic loss criteria (i.e. the mean) to estimate V . However, even with the median and
mode estimates, the estimation of V maintains. This had to be checked since the posterior
conditional of V (differently from θ) is skewed (equation 4.9). Notice that similar results
were obtained for the other individuals/genes.
5.4.3 The robust model
Another aspect of the model that must be considered is the distributional assumption of
the mean of the exonic coverage ratios: θ ∼ tν(µ, τ2). While a parameter of centrality and
variability (µ and τ) would be evident to govern the exonic coverage ratios, the use of an
additional parameter ν of robustness/extremeness, with no biological interpretability in the
context of the CNV detection and identification problem, can be arguable. The importance
of ν can be better evaluated considering its effect on θ and V .
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Figure 5.4. Analysis of four summary statistics (mean, standard deviation, skewness and kurtosis) for
the observed normalized coverage ratios zij =
yij−θj√
Vj
, considering the quadratic loss posterior estimates
of the model parameters. The blue vertical lines correspond to exon-specific 0.95 simulated intervals,
considering the distribution of the corresponding summary statistics for a nj random draw of a standard
normal distribution.
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Using the converged, mixed and independent MCMC random draws of the posterior dis-
tribution, we analyze the joint behavior of ν and θ and V model parameters. The central
estimations of θ and V do not significantly change according to ν, however their precision
is affected, being higher when 1/ν → 1. In addition, we must refer that the support of the
posterior marginal of 1/ν is clearly in the robust region of the model, having support between
0.6 and 1 in most of the analysis, which corresponds to a t-distribution with 1-1.6 degrees
of freedom. Thus, the use of a robust model shows itself appropriate for the detection and
identification of CNVs, particularly when considering the normal alternative (which would
assume 1/ν → 0).
Figure 5.5. Joint probability distribution of ν with the model parameters θ and V for the
individual 6 and BRCA2 gene. For sake of simplicity, the particular cases of the first element
of the exonic coverage ration mean and variance vectors are shown (θ1 and V1).
5.5 Posterior predictive checking
In addition to the model assumptions, we may want to know the predictive quality of the
model. The predictive posterior distribution p(y∗|y) can be used to assess model predictabil-
ity in a straightforward way. Lets consider a random draw of the posterior distribution. The
values of θ and V can be used to replicate, by simulation, the observed values. The close
the replicated values are from the observations, the higher is the model predictive quality.
The replicates and the observed values are generally compared using summary statistics
of interest T (.). Here we look closer to the mean and standard deviation. Once several
replicated summary statistics are simulated, they can be compared with the corresponding
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summary statistic, calculated with the observed data, and a Bayesian p-value can be assessed:
P [T (y∗) < T (y)] (Gelman et al., 2014g). The Bayesian p-values should approach 0.5 in good
predictive conditions, while extreme values (near to 0 or 1), express poor predictive quality
of the summary statistic (Gelman et al., 2014g).
Using the predictive distribution we found that the mean and the variance are generally
well predicted by the model (figure 5.6). For some specific exons, we observed that the
variance of the coverage ratio possessed Bayesian p-values near to 0. Considering that we
are calculating P [T (y∗) < T (y)] = 0 then we conclude that T (y∗) > T (y). This result is
in congruence with the analysis we performed when checking for data normality, in which
some exonic variances were overestimated.
Figure 5.6. Model predictability analysis. The Bayesian p-values are shown for both, the mean
(left plot) and the variance (right plot) summary statistics.
The predictive performance of the hierarchical robust model suggests it is able to produce
accurate and precise inferences to detect and identify exonic CNVs. Some exonic variances
showed to be overestimated, which is of minor importance, because we know that the
coverage ratio means (i.e. the CNV-type) are being properly predicted and in addition,
the overestimated variances avert the existence of false positives.
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5.6 Inference of CNVs
Apart from the model assessment, another important characteristic of a model (if not the
most important) is to give a proper answer to the problem it was meant to solve. In our
case we pretend to know if the Bayesian robust model implemented here is capable of detect
and identify CNVs in the BRCA1 and BRCA2 genes.
5.6.1 CNV detection
Hyperparameters can be used to detect CNVs, that is, to conclude whether a CNV is present
in one or more exons of a particular gene, prior to the attempt to characterize the CNVs
once they were discovered to exist. Most of the analysis will return negative results, and
advance with an inferential strategy to rapidly indicate those that require a fine analysis is
of clear interest.
The comparison of the hyperparameters estimates can provide some insight on the CNV
detection (figure 5.7). µ do not show any special behavior in the presence of CNVs. 1/ν
and τ hyperparameters were expected to be more sensible to the presence of CNVs, as
they are measures of the exonic coverage ratios variability. While the 1/ν parameter is
not particularly associated with the presence of CNVs, the τ parameter is. We checked the
estimations of τ in the t-model for the analyzed individuals and found that in the three cases
in which CNVs were detected, the scale parameter was higher (red arrows, figure 5.7). The
definition of thresholds to perform the detection of CNVs would still require more sampling,
particularly of CNV-positive cases, but τ can be appointed as a promising parameter.
5.6.2 CNV identification
The identification phase includes the characterization of exonic CNVs with particular interest
in providing a criteria of statistical evidence. It is thus necessary to advance a strategy that
not only characterize the type of structural variation we have observed (CNV-type), as well
as, provide a quality parameter of such characterization, i.e. a measure of how much one
can be sure about the presence of a CNV in a particular exon, considering a regular case.
Here the regular case in the standard coverage.
CNVs are, by nature, discrete categories that must be considered in the identification
process. Thus, we may want to discretize the log coverage ratios (a continuous variable) into
meaningful intervals. Another aspect of the CNV identification that must be considered, is
the possibility of its occurrence in heterozygosity. Humans receive two copies of each gene,
and the duplicated (or the deleted) CNVs could have affected only one copy or both (case in
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Figure 5.7. Representation of the model hyper parameters, µ (blue), τ (red) and ν (yellow) for
each of the case study individuals and genes. Cases where CNVs have been reported are indicated
with a red arrow.
which we would have a homozygous CNV). Consider the following example. A homozygous
duplication (2-2) is likely to produced, in average, duplicated coverage ratios, however, in
an heterozygous duplication (1-2) the coverage ratio would be, in average 1.5. Note that an
exonic duplication and deletion in heterozygosity (0-2) would be confounded with a normal
individual, at least considering the θj estimate (Vj would be most certainty higher). It must
be stressed that these confounding scenarios are not a limitation of the model, but of the
experimental technique.
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Notice that we used a standardize coverage that considers only the deviance from the
expected behavior (1) we should be aware that our normal region is between the gain in
heterozygorizty (0.5) and the loss in heterozygozity (-0.5).
The visual inspection of θ and V parameters appears informative for the CNV identification
(figure 5.8). The θ estimates in the individuals 7 and 9 for the BRCA1 and BRCA2 genes
are clearly suggesting the presence of CNVs, because the exon-specific θj values lied out of
the normal region of the coverage ratio (i.e. 0.5 < coverage ratio < −0.5). The non-altered
(or neutral) region corresponds to the interval where the coverage readings of the case study
individual follows the same pattern as the standard individual (here, the individual 10).
Apart from the visual inspection, we would want an inferential measure to validate the
identification of potential CNVs. Here we follow the Bayesian hypothesis testing and ad-
vance with a Bayes factor approach on the predictive distribution. The Bayes factors were
calculated considering the probability of the predicted exonic coverage ratio lies out of the
normal region (homozygous for 1 copy).
BF =
p(y∗|y > 0.5) + p(y∗|y < −05)
p(−0.5 < y∗|y < 0.5) (5.1)
The predictive Bayes factors are calculated favoring the existence of CNVs.
Exon-specific Bayes factors can be used to determined the existence of a CNV in a particular
exon if the j-th Bayes factor is higher than 1. Table 5.2 depicts some Bayes factors higher
than 1, which correspond to those exons that possess CNVs (in bold). A closer analysis
of the table is clear to show that artifact CNVs possess Bayes factors that are always less
than 1, while true exonic-CNVs always possess Bayes factors higher than 2. Advancing the
presence of a CNV on a particular exon j, based on a rule as BFj > 2, should be enough to
accurately indicate the true altered exons.
Once evidence on the presence of a CNV in a particular exon exists, we would want to
determine its type. Using the same approach we have used to calculated the probability of
a certain exonic coverage ratio lie out of the normal region, we compute the probability
of a certain exonic coverage ratio lie within CNV-type regions we might be interested.
Considering the genetic aspects of the CNVs, we would be interested in delimit the coverage
ratio in portions that should include the {−1,−0.5, 1, ...} CNV-types. We exclude the 1 copy
type (normal homozygous), because this analysis is only opportune when evidence on the
presence of a CNV exists.
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Individual 7 Individual 9
exon BRCA1 BRCA2 BRCA1 BRCA2
2 0.000 0.000 0.002 0.000
3 0.000 0.000 0.000 0.001
4 0.000 0.072 0.000 0.000
5 0.000 0.014 0.000 0.000
6 0.000 0.128 0.002 0.000
7 0.000 0.001 0.000 0.000
8 0.000 0.000 0.000 0.000
9 0.000 0.026 0.000 0.037
10 0.125 0.068 0.034 0.000
11 0.000 0.045 0.000 0.033
12 0.292 0.001 0.034 0.000
13 0.001 0.000 0.000 0.110
14 0.003 0.000 0.558 0.051
15 0.000 0.000 0.082 0.018
16 0.000 0.012 19.370 0.000
17 0.000 0.000 0.000 0.351
18 0.000 0.203 0.000 0.000
19 0.000 0.045 0.000 2.403
20 0.000 2.789 0.000 5.411
21 0.000 0.156 0.000 0.002
22 0.000 0.000 0.000 0.000
23 0.003 0.000 0.000 0.006
24 0.000 0.053
25 0.004 0.000
26 0.023 0.000
27 0.005 0.120
Table 5.2. Bayes factors calculated for the individuals 7 and 9, in both the BRCA1
and BRCA2 genes. The predictive Bayes factor was computed considering the
probability of a certain exonic coverage ratio lie out of the normal region (homozygous
for 1 copy): 1 − p(0.5 < y∗|y > −0.5). Bayes factors can be easily computed
considering that yij are normally distributed.
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The analysis of the table 5.3 shows the existence of CNVs in heterozygosity (duplication in
only one of the gene copies) for all the identified exonic CNVs: the 0.5 coverage ratio region
was the one that returned higher probability for the reported cases of CNV presence.
CNV-type
Individual Gene exon -1 -0.5 0.5 1 1.5
7 BRCA2 20 0.002 0.016 0.283 0.256 0.136
9 BRCA1 16 0.000 0.000 0.946 0.000 0.000
9 BRCA2 19 0.000 0.001 0.472 0.213 0.023
9 BRCA2 20 0.000 0.000 0.537 0.302 0.023
Table 5.3. Probability of different CNV-types for those exons in which was obtained
statistical evidence for the existence of CNVs. Non-integer values corresponds to
heterozygous states, i.e. alterations that affect only one of the two gene copies in the
individual’s genome.
5.6.3 Final comments
The main conclusions of the BRCA1 and BRCA2 case study, considering the analysis of
the model’s assumptions, its predictive quality and its ability to answer to the biological
problem, are:
• The data standardization using a reference coverage appears to be unaffected to the
existence of coverage readings from CNV-regions. The standardization was proved to
be unnecessary in this case study.
• The use of non-informative priors for the hyperparameters (µ, τ, 1/ν) does not affect the
model’s performance, and its conditional posterior distributions appear to effectively
capture data information.
• The likelihood of the model shows weak signs of normality, but the posterior estimates
of the model parameters θ and V are satisfactory describing the data. In both
the BRCA1 and BRCA2 genes, some variances of the exonic coverage ratios were
overestimated which does not seem to compromise the identification of CNVs. In a
way, this feature protects the existence of false positives.
• The use of a robust distribution for the means of the exonic coverage ratios adds
explanatory value to the model. In both genes we verify that the posterior estimations
of ν were in the robust region of the model, suggesting that ν is a necessary and
important parameter to explain data.
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• An increased scale parameter (τ) appears to be a promising pattern to detect, in a
preliminary phase, the presence of CNVs.
• The identification of CNVs proved straightforward using predictive exon-specific Bayes
factors. Values above 2 appear sufficient to properly identify true CNVs, and most
important, distinguished artificial CNVs.
Chapter 6
Conclusion
In this thesis, we advanced a robust inferential Bayesian model for the detection and identi-
fication of CNVs in protein-coding genes, considering a reference coverage. The performance
of the model was evaluated in a case study involving the BRCA1 and BRCA2 genes, what
gives additional insight on the statistical aspects of the model. Despite the model provided a
satisfactory answer to the biological problem of CNVs identification, there are improvements
which are important to discuss. Chapter 6 discusses the performance of the hierarchical
robust model from an analytical and an applied point-of-view.
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6.1 Reference coverage
The existence of a reference coverage prevents the use of a longitudinal standardization
(expression 3.1) which is a great improvement. While it seems to be a better option, the
standardization based on a reference coverage must be properly discussed (expression 3.2).
6.1.1 Limitations of the reference coverage correction
One of the limitations of the reference coverage standardization is the existence of CNV
coverage readings in the tested individuals/genes. As we have already referred, during the
standardization phase, we want the potential CNV coverage readings interfere as little as
possible, so they can be more easily identified later using a proper statistical analysis. In the
BRCA1 and BRCA2 case study, a standardization based on a linear relationship between
the coverages was verified to vary little whether the coverage readings of exons with CNVs
were used or excluded.
Other concern is the number of exons with CNVs. In the BRCA1 and BRCA2 case study
we have a maximum of 2 exonic CNVs (BRCA2, individual 9), however it can be the case
of a higher number. In this scenario a possible minimizing approach would be the use
of the median regressor to estimate E[C1|C0], which would be less sensitive to extreme
observations. Another possible approach would be to remove a certain percentage of the
most extreme observations considering a preliminary estimation of E[C1|C0]. However, this
alternative could be worthless because it would be difficult to determine which percentage
of points to remove and also, we observed in the case study that the CNV coverage readings
are not always the outlier observations (considering the standardization line; figure 5.2).
6.2 The hierarchical Bayesian model
The hierarchical robust model was shown to be a good approach to detect and identify
CNVs. There are however some distributional aspects of the model that required further
discussion.
6.2.1 The hyperparameters: priors and posteriors
The hyperparameters of the model (µ, τ and ν) were assumed as having an uniform prior
distribution, which is an uninformative type of prior. The marginal posterior distribu-
tions of the hyperparameters showed to be quite informative (figure 5.2), suggesting that
hyperparameters are properly capturing data information. In the hierarchical model, the
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hyperparameters affect the data only through the model parameters (θ and V ), and the
combined data of the J exons appears enough to produce informative posterior distributions.
If we had additional information on the hyperparameters or wanted to integrate information
of previous analysis, we may have opted for informative priors. A prior distribution of the
exponential family, would be a recommended option for µ and τ , since their conditional
posteriors have both an exponential kernel (equations 4.6 and 4.7). For the robustness
parameter ν it would be more difficult to define an informative prior. It must be considered
that the conditional posterior distribution of this parameter is quite complex (equation 4.10),
and thus, it would be challenging to find an informative prior without further analytical
and numerical complications. Considering both the density and the support of the marginal
posterior distribution of 1/ν (figure 5.3), a Beta prior distribution appears suitable. However,
it must be noted that the conditional posterior distribution of ν (equation 4.10) is not Beta-
conjugated.
Note that using informative priors for the hyperparameters do not necessarily imply prior-
dominated posteriors, we may (and should) chose prior parameters that result in general
priors.
6.2.2 The normal likelihood
One of the limiting aspects of the hierarchical Bayesian model was the normality of the
observed coverage ratios. It was found that some of the variances were overestimated. In
the hierarchical model, the exon-specific coverage ratio variances are estimated as a weighted
combination of the complete pool and the none at all (Gelman et al., 2014f).
Vj = λjs
2
.j + (1− λj)s2..
It seems that the presence of some outliers in the observed coverage ratios is promoting the
contribution of the s2.. factor in the estimation of V , leading to its overestimation in some
cases. That does not imply, at any rate, that we should leave the heterocedastic assumption,
but instead that we should consider other likelihood models.
A natural model for the likelihood would definitely be a robust distribution, as the discussed
t-student distribution. A t-student likelihood,
yij ∼ tη(θ, σ2)
would be able to model the variability of the observations at two levels: the variation around
the mean (σ) and the existence of outlier events (η). In fact, the same approach proved useful
describing the exonic coverage ratio means.
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Considering the independence of the y.j observations and the exchangeability of the exonic
coverage ratio distributions, the likelihood takes the form,
p(y|θ, σ, η) =
∏
j
∏
i
Γ
(
ηj+1
2
)
Γ
(ηj
2
)√
ηjpiσj
[
1 +
1
ηj
(
yij − θj
σj
)2]− ηj+12
There are however some aspects to consider on the t-sample model:
• The existence of a new parameter η must be included in the model with an hierar-
chical dependence on the hyperparameters. A possible way is to expand the model,
considering the correspondence between the variances on the normal and the t-student
likelihoods.
V =
η + 2
η
σ2
• The likelihood does not have a simple expression. Most of the parameters which have a
known conditional posterior in the normal likelihood, would have a complex expressions
in the t-student likelihood, particularly the conditional posteriors of θ and σ. The prior
and data kernels of θ and σ would no longer be conjugated.
• θ, τ and η would all required a Metropolis-Hastings step during the MCMC sampling.
That results in 3J Metropolis-Hastings operations per iterate, that would certainly
compromise the efficiency of the computational algorithm.
In sum, it would be difficult, if not impracticable, to develop a robust hierarchical model
with a robust likelihood. The remaining option is to consider the consequences of the
overestimation of some variances and adapt the inferential approach accordingly. However,
we must refer they should be minimal once the accuracy of our model is good.
6.3 The classical solution revisited
In Chapter 4 a classical solution to the CNV detection and identification problem was
advanced, but when considering the inferential limitations of the ANOVA, it was not explored
further. It would be important, at this point, to compare the results of both approaches.
We proceed to the implementation of ANOVA and Tuckey pairwise multiple comparisons at
the 0.05 level.
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All the analyzed genes/individuals indicate that exist at leat one exon with a differentiated
θj (p-value less than 0.001 in all cases), thus suggesting that we should use differentiated
θj for (one, more than one or all) the coverage ratio means. Using the classical approach
to detect CNVs in a preliminary phase, would be worthless, being the level 0.05 excessively
discriminant to detect different means. In the ANOVA approach the main difficulty would
be to define a p-value, which would properly detect the existence of CNVs. In the Bayesian
approach we take advantage of the hyperparameter estimates to identify potential statistics
of interest. We found the scale of the exonic coverage ratio means a promising statistic to
detect CNVs, but others could be considered, including distributional characteristics of the
hyperparameters (quantiles, higher order moments, etc.).
exon 2 0.95 lower 0.95 upper adjusted p-value
3 0.156 0.375 0.000
4 0.024 0.270 0.003
5 0.254 0.551 0.000
6 -0.015 0.301 0.143
7 0.071 0.316 0.000
8 0.296 0.593 0.000
9 0.151 0.396 0.000
10 0.122 0.322 0.000
11 0.166 0.361 0.000
12 0.009 0.262 0.021
13 0.130 0.402 0.000
14 0.103 0.312 0.000
15 0.225 0.453 0.000
16 -0.022 0.204 0.346
17 0.416 0.645 0.000
18 0.139 0.351 0.000
19 0.850 1.082 0.000
20 0.975 1.210 0.000
21 0.255 0.497 0.000
22 0.154 0.378 0.000
23 0.292 0.523 0.000
24 0.140 0.377 0.000
25 0.044 0.263 0.000
26 0.015 0.249 0.009
27 0.176 0.380 0.000
Table 6.1. Tuckey tests for the coverage ratio mean comparisons.
Comparisons of the exon 2 with all the other exons in analysis in the
individual 9, gene BRCA2. The p-values (Bonferroni adjusted) are
based on the alternative hypothesis of the compared exonic coverage
ratios are different.
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We proceed with the Tuckey tests to retrieve conclusions about the θ parameter. We use
the CNV coverage ratios from the individual 9 and the gene BRCA2, for which two CNVs
have been described. Firstly, the output is a tremendous table: for a gene with J exons we
would have to analyze (J2 − J)/2 outputs. In our case we obtained 325 mean comparisons.
Secondly, we obtain that the pairwise Tuckey tests return significant results in most of the
cases. Table 6.1 shows part of the output Tuckey tests, corresponding to the 2nd exon mean
comparisons. We observed that most of the exonic coverage ratio comparisons returned
significant results, meaning that the coverage ratio mean of the exon 2 is different from most
of the other exons (the same can be concluded analyzing the 0.95 confidence intervals). As
we know, the exon 2 is not an altered exon . Again, a p-value of 0.05 is too discriminant
for our purpose, and the CNV identification phase is prone to return more θ categories than
actually exist.
In conclusion, the Bayesian approach contrasts with the Classical approach, mainly because
the first provides a natural way for inference, in line with the meaningful hypothesis the
biological problem requires. The Classical hypothesis testing introduces rigidity in the
inference, that in the context of the CNV detection and identification problem is of no
value.
6.4 Final remarks
• Main objective: To create an inferential model that permits to identify CNVs on
the exonic regions of genes, using the next-generation sequencing coverage readings.
Our main objective was accomplished since we were able to satisfactory identify and
characterize exonic CNVs.
• Objective 1. To present a suitable strategy to deal with the coverage noise (i.e. the
coverage variations that are not related with the presence of exonic CNVs).
The coverage ratios are calculated using the next-generation sequencing technique
and are thus, dependent on several experimental variables (the quantity of reagents,
the DNA in the sample and the experimental design to assess the genomic regions
of interest). This sources of variability are not due to the presence of CNVs, and
using a coverage standardization by a reference genome, appears to effectively remove
the noise introduce by the experimental variables. Indeed, we observed that coverage
profiles from different individuals were proportional, feature that contributed for the
easy removal of the experiment-induced variability.
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• Objective 2. To construct a probabilistic model for the observed exonic coverage
ratio modeling.
We use the hierarchical Bayesian model for the exon coverage ratio modeling, and
considering the discussion we have been doing, we were able to proper identify CNVs
in protein-coding genes. Our model is overestimating some of the exonic variances,
without however compromising the accuracy of the CNV identification. We should
consider improvements on the normal likelihood, as the use of a robust sample model
or, alternatively, the assessment of the model precision using known CNV cases, as
we have done here. Notice that we found this feature not limitative for the CNV
identification, since θ, the parameter that indicated the CNV-type, is well predicted
by the model.
• Objective 3. To create an inferential framework to detect the presence of CNVs in
protein-coding genes, in a early phase of the CNVs analysis.
We have shown to be able to detect CNVs using the scale parameter of the t-student
distribution. This parameter showed elevated in cases where CNVs where present.
More sample will be needed however, to determine a proper threshold that distinguishes
the cases we should devote a proper analysis from the normal ones.
• Objective 4. To develop an inferential framework to identify CNVs, when a potential
altered-gene is detected. The identification of CNVs includes determining the type of
exonic CNVs (deletion, duplication, etc.).
We were able, with the use of exon-specific Bayes factors, to determine the existence of
a CNVs in specific exons, and additionally, characterize the type of CNV (heterozigous,
homozigous, deletions or duplications). For the BRCA1 and BRCA2 genes we were
able to advance a Bayes factor threshold (BF > 2) that allows the identification of
CNVs and, more important, the proper exclusion of artifact CNVs. This procedure
may be generalized for any gene we might want to study.
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Appendix A
Computational implementation
During the development of this thesis we developed R codes with the objective of implement
the hierarchical Bayesian model. The outline of the code organization is represented in figure
A.1. The code was developed in four phases.
Figure A.1. Computation implementation outline. The input and output
parameters and/or files are represented in blue and red arrows, respectively.
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The implementation of the hierarchical Bayesian model requires the definition of several
parameters, namely, the number of iterates (iter), the number of chains (chains) and the
number of utile iterations (uiter). The iter/uiter ratio is, by definition, the thinning
fraction. Other parameters are related with the MCMC part of the algorithm, as the
standard deviation of the proposal distribution (snu), the leapfrog discretization factor
(epson) and the mass matrix (M).
iter <- 30000
chains <- 2
uiter <- 1500
snu <- 0.1
epson <- 0.1
M <- rep(1,D)
The algorithm begins by extracting the data from the .bam and .bai files from the case
study and the reference individuals. A coordinate file, with the information of the genes
to analyze and the genomic coordinates to extract the coverage, must exist in the working
directory. The algorithm proceeds with the calculation of the coverage ratio for each of the
case study individual in the working directory.
#READ DATA
#PACKAGES
library(rbamtools)
path <- getwd()
#COORDINATE FILE
coord <- read.table(paste(path,"coordinates.txt",sep="/"),header=T)
gene <- as.vector(unique(coord[,1]))
genei <- matrix(ncol=4,nrow=length(gene))
for (i in 1:length(gene)) {
genei[i,1:4] <- c(gene[i],coord[which(coord[,1]== gene[i])[1],2],
coord[which(coord[,1]== gene[i])[1],3],
coord[which(coord[,1]== gene[i])[1],4])
}
#CONTROL.BAM
control <- bamReader(paste(path,"control.bam",sep="/"))
load.index(control,paste(paste(path,"control.bam",sep="/"),"bai",sep="."))
index.initialized(control)
files <- list.files(path)
files <- files[which(substr(files,nchar(files)-2,nchar(files))=="bam")]
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files <- files[-which(files == "control.bam")] #all the files in the directory
file <- substr(files,1,nchar(files)-4)
for (j in 1:length(files)) {
sample <- bamReader(paste(path,files[j],sep="/"))
load.index(sample,paste(paste(path,files[j],sep="/"),"bai",sep="."))
index.initialized(sample)
rdf <- getRefData(sample)
fpath <- paste(path,file[j],sep="/")
dir.create(fpath)
for (i in 1:length(gene)) {
gpath <- paste(fpath,gene[i],sep="/")
dir.create(gpath)
#EXONS
exoni <- coord[which(coord[,1] == gene[i]),5:7]
#COVERAGE
scov <- c()
ccov <- c()
exon <- c()
for (k in 1:dim(exoni)[1]){
exon <- c(exon,rep(exoni[k,1],exoni[k,3]-exoni[k,2]+1))
exonc <- as.integer(c(as.numeric(genei[i,2])-1,exoni[k,2],exoni[k,3]))
scov <- c(scov,getDepth(alignDepth(bamRange(sample ,exonc))))
ccov <- c(ccov,getDepth(alignDepth(bamRange(control,exonc))))
}
ycov <- scov/1000
xcov <- ccov/1000
a <- sum(ycov*xcov)/sum(xcov*xcov)
rcov <- scov/(a*ccov) - 1
write.table(cbind(exon,rcov),paste(gpath,"edata.txt",sep="/"),row.names=F,quote=F)
data <- matrix(NA,ncol=4,nrow=dim(exoni)[1])
for (k in 1:1:dim(exoni)[1]){
ercov <- rcov[which(exon == exoni[k,1])]
data[k,1:4] <- c(exoni[k,1],mean(ercov),var(ercov),length(ercov))
}
colnames(data) <- c("exon","mj","s2j","nj")
write.table(data,paste(gpath,paste("data.txt"),sep="/"),row.names=F,quote=F)
}
}
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Once the data is extracted, the algorithm implements the MCMC step. It includes the Gibbs-
Metropolis-Hastings and the Hamiltonian Monte Carlo algorithms that proceed iteratively
and produce a chain.txt file, which contains usim iterates for each of parameters in analysis.
#HIERARCHICAL BAYES
#FUNCTIONS
rnu <- function(nu,tau,V,snu) {
inu <- rnorm(1,1/nu,snu)
if (inu <= 0 | inu >1) {
jp <- 0
} else {
nus <- 1/inu
r <- exp( nus*( J*log(nus/2)/2 + J*log(tau) -
sum(log(V))/2 - tau*tau*sum(1/V)/2 ) - J*lgamma(nus/2) -
nu*( J*log(nu /2)/2 + J*log(tau) -
sum(log(V))/2 - tau*tau*sum(1/V)/2 ) + J*lgamma(nu /2) )
if (runif(1) < r) {
nu <- nus
}
jp <- min(r,1)
}
return(c(nu,jp))
}
lpost <- function(lambda,mj,s2j,nj) {
J <- length(lambda)/2-1.5
mu <- lambda[1]
tau <- exp(lambda[2])
theta <- lambda[3:(2+J)]
V <- exp(lambda[(3+J):(2*J+2)])
nu <- exp(lambda[2*J+3])
lpost <- J*nu*log(nu/2)/2 - J*lgamma(nu/2) + nu*J*log(tau) -
sum((nu*tau^2 + (theta-mu)^2 + nj*(mj-theta)^2 + (nj-1)*s2j )/V)/2 -
sum((nu+3+nj)*log(V))/2 +
log(tau) + sum(log(V)) + log(nu)
return(lpost)
}
lgrad <- function(lambda,mj,s2j,nj) {
J <- length(lambda)/2-1.5
mu <- lambda[1]
tau <- exp(lambda[2])
theta <- lambda[3:(2+J)]
V <- exp(lambda[(3+J):(2*J+2)])
nu <- exp(lambda[2*J+3])
grad <- c( sum((theta-mu)/V),
nu*J - nu*tau*tau*sum(1/V) + 1,
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(mu + nj*mj - (1+nj)*theta)/V,
(nu*tau*tau+(theta-mu)^2+nj*(mj-theta)^2+(nj-1)*s2j)/(2*V) - (nu+3+nj)/2 + 1,
nu*(J*log(nu/2)/2 + J/2 - J*digamma(nu/2)/2 + J*log(tau) - sum(log(V))/2 -
tau*tau*sum(1/V)/2 ) + 1 )
return(grad)
}
hmc <- function(lambda,M,epson,mj,s2j,nj){
L <- floor(1/epson)-1
D <- length(lambda)
#RANDOM MOMENTUM
psi <- rnorm(D,0,sqrt(M))
lambdai <- lambda
lposti <- lpost(lambda,mj,s2j,nj) - sum(psi*psi/M)/2
#LEAPFROG STEP
psi <- psi + epson*lgrad(lambda,mj,s2j,nj)/2
for (i in 2:(L-1)) {
lambda <- lambda + epson*psi/M
psi <- psi + epson*lgrad(lambda,mj,s2j,nj)
}
psi <- psi + epson*lgrad(lambda,mj,s2j,nj)/2
#METROPOLIS STEP
r <- exp(lpost(lambda,mj,s2j,nj) - sum(psi*psi/M)/2 - lposti)
if (is.na(r) == T) { r <- 0 }
if ( runif(1) <= min(1,r) ) {
return(c(1,lambda))
} else {
return(0)
}
}
#HIERARCHICAL ROBUST MODEL
for (j in 1:length(files)) {
for (i in 1:length(gene)) {
gpath <- paste(path,file[j],gene[i],sep="/")
data <- read.table(paste(gpath,"data.txt",sep="/"),header=T)
#STATISTICS
mj <- data[,2]
s2j <- data[,3]
nj <- data[,4]
J <- dim(data)[1]
D <- 2*J+3
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#RUN
usims <- seq(iter/uiter,iter,iter/uiter)
for (k in 1:chains){
nu <- 1/runif(1,0,1)
mu <- rnorm(1,mean(mj),sd(mj))
tau <- runif(1,0,2*sd(mj))
V <- runif(J,0,2*mean(s2j))
p <- 1
gibbs <- matrix(NA,ncol=4+J*2,nrow=uiter)
for (m in 1:iter){
theta <- rnorm(J,(mu+mj*nj)/(nj+1),sqrt(V/(nj+1)))
V <- (nu*tau^2+(theta-mu)^2+nj*(mj-theta)^2+(nj-1)*s2j)/rchisq(J,nu+nj+1)
mu <- rnorm(1,sum(theta/V)/sum(1/V),sqrt(1/sum(1/V)))
tau <- sqrt(rgamma(1,J*nu/2+1,nu*sum(1/V)/2))
sam <- rnu(nu,tau,V,snu)
nu <- sam[1]
phmc <- hmc(lambda=c(mu,log(tau),theta,log(V),log(nu)),M,epson,mj,s2j,nj)
if (phmc[1] == 1) {
lambda <- phmc[-1]
mu <- lambda[1]
tau <- exp(lambda[2])
theta <- lambda[3:(2+J)]
V <- exp(lambda[(3+J):(2*J+2)])
nu <- exp(lambda[2*J+3])
} else {
}
if (m == usims[p]) {
gibbs[p,] <- c(mu,tau,theta,V,1/nu,sam[2])
p <- p+1
}
}
colnames(gibbs) <- c( "mu","tau",paste("theta",data[,1],sep=""),
paste("V" ,data[,1],sep=""),"inu","jp" )
write.table(gibbs,paste(gpath,paste("chain",k,".txt",sep=""),sep="/"),row.names=F,quote=F)
}
}
}
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During the diagnose step the MCMC iterates are visually and numerically analysed. For
each chain, the first 1/3 of the iterates are eliminated. The remaining iterates are evaluated
for convergence, mixing and correlation. Once these criteria are respected a file with
the converged, mixed and independent iterates is produced (rdraw.txt) along with the
parameters estimates according to the quadratic loss criteria (mean and standard deviation).
#DIAGNOSE
for (j in 1:length(file)) {
for (i in 1:length(gene)) {
gpath <- paste(path,file[j],gene[i],sep="/")
cfile <- list.files(gpath)
cfile <- cfile[which(substr(cfile,1,5)=="chain")]
chains <- length(cfile)
#CONVERGENCE AND MIXING
rdraw <- NULL
for (k in 1:chains) {
cdraw <- as.matrix( read.table(paste(gpath,paste("chain",k,".txt",sep=""),sep="/"),
header=T) )
rdraw <- rbind(rdraw,cdraw[501:1500,])
}
write.table(rdraw,paste(gpath,"rdraw.txt",sep="/"),row.names=F,quote=F)
it <- 1:1000
pdf(paste(gpath,"convergence.pdf",sep="/"),width = 6, height = 4.5)
par(mfrow=c(1,3))
for (k in c(1,2,dim(rdraw)[2]-1)) {
plot(it,rdraw[it,k])
for (l in 2:chains) {
points(it,rdraw[it+(l-1)*1000,k],col=l)
}
}
dev.off()
#PARAMETERS
par <- t(rbind(apply(rdraw,2,mean),apply(rdraw,2,sd)))
colnames(par) <- c("mean","sd")
write.table(par,paste(gpath,"par.txt",sep="/"),row.names=T,quote=F)
}
}
The identification phase includes the visual inspection of the exonic parameters (θ and V )
and the calculation of the predicted Bayes factors for each exon. Two output files are
produced, respectively: exonpar.pdf and pcnv.txt.
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#INDENTIFICATION
for (j in 1:length(file)) {
for (i in 1:length(gene)) {
li <- c(-0.5,0.5)
gpath <- paste(path,file[j],gene[i],sep="/")
data <- read.table(paste(gpath,"data.txt",sep="/"),header=T)
param <- read.table(paste(gpath,"par.txt",sep="/"),header=T)
J <- dim(param)[1]/2 - 2
theta <- param[3:(J+2),1]
V <- param[(J+3):(2*J+2),1]
int <- data[,1]
v <- sqrt(V)
pdf(paste(gpath,"exonpar.pdf",sep="/"),width = 6.5, height = 4)
plot(int,rep(-100,J),ylim=c(li[1]-0.5,li[2]+0.5),xlab="exons",ylab="CRatio",
main=paste("Individual ",j," ",gene[i],sep=""))
abline(h=0,col="gray")
abline(h=c(li[1],li[2]),col="red")
segments(x0=int,y0=theta-2*v,x1=int,y1=theta+2*v,col="dodgerblue")
points(int,theta,col="blue")
dev.off()
#PRED BAYES FACTOR
rdraw <- as.matrix( read.table(paste(gpath,"rdraw.txt",sep="/"),header=T))
rtheta <- rdraw[1:2000,3:(J+2)]
rv <- sqrt(rdraw[1:2000,(J+3):(2*J+2)])
pcnv <- matrix(NA,ncol=2,nrow=J)
for (k in 1:J){
pred <- rnorm(2000,rtheta[,k],rv[,k])
prob <- 1 - pnorm(li[2],mean(pred),sd(pred)) + pnorm(li[1],mean(pred),sd(pred))
pcnv[k,] <- c(int[k], prob/(1-prob))
}
colnames(pcnv) <- c("exon","pbayesfactor")
write.table(pcnv,paste(gpath,"pcnv.txt",sep="/"),row.names=F,quote=F)
}
}
